

DCP3 Series Acknowledgments

Disease Control Priorities, third edition (*DCP3*) compiles the global health knowledge of institutions and experts from around the world, a task that required the efforts of over 500 individuals, including volume editors, chapter authors, peer reviewers, advisory committee members, and research and staff assistants. For each of these contributions we convey our acknowledgement and appreciation. First and foremost, we would like to thank our 31 volume editors who provided the intellectual vision for their volumes based on years of professional work in their respective fields, and then dedicated long hours to reviewing each chapter, providing leadership and guidance to authors, and framing and writing the summary chapters. We also thank our chapter authors who collectively volunteered their time and expertise to writing over 160 comprehensive, evidence-based chapters.

We owe immense gratitude to the institutional sponsor of this effort: The Bill & Melinda Gates Foundation. The Foundation provided sole financial support of the Disease Control Priorities Network. Many thanks to Program Officers Kathy Cahill, Philip Setel, Carol Medlin, and (currently) Damian Walker for their thoughtful interactions, guidance, and encouragement over the life of the project. We also wish to thank Jaime Sepúlveda for his longstanding support, including chairing the Advisory Committee for the second edition and, more recently, demonstrating his vision for *DCP3* while he was a special advisor to the Gates Foundation. We are also grateful to the University of Washington's Department of Global Health and successive chairs King Holmes and Judy Wasserheit for providing a home base for the *DCP3* Secretariat, which included intellectual collaboration, logistical coordination, and administrative support.

We thank the many contractors and consultants who provided support to specific volumes in the form of economic analytical work, volume coordination, chapter drafting, and meeting organization: the Center for Disease Dynamics, Economics, & Policy; Center for Chronic Disease Control; Center for Global Health Research; Emory University; Evidence to Policy Initiative; Public Health Foundation of India; QURE Healthcare; University of California, San Francisco; University of Waterloo; University of Queensland; and the World Health Organization.

We are tremendously grateful for the wisdom and guidance provided by our advisory committee to the editors. Steered by Chair Anne Mills, the advisory committee assures quality and intellectual rigor of the highest order for *DCP3*.

The U.S. Institute of Medicine, in collaboration with the Interacademy Medical Panel, coordinated the peer-review process for all *DCP3* chapters. Patrick Kelley, Gillian Buckley, Megan Ginivan, and Rachel Pittluck managed this effort and provided critical and substantive input.

The World Bank External and Corporate Relations Publishing and Knowledge division provided exceptional guidance and support throughout the demanding production and design process. We would particularly like to thank Carlos Rossel, the publisher; Mary Fisk, Nancy Lammers, Devlan O'Connor, Rumit Pancholi, and Deborah Naylor for their diligence and expertise. Additionally, we thank Jose de Buerba, Mario Trubiano, Yulia Ivanova, and Chiamaka Osuagwu of the World Bank for providing professional counsel on communications and marketing strategies.

Several U.S. and international institutions contributed to the organization and execution of meetings that supported the preparation and dissemination of *DCP3*.

We would like to express our appreciation to the following institutions:

- University of Bergen, consultation on equity (June 2011)
- University of California, San Francisco, surgery volume consultations (April 2012, October 2013, February 2014)
- Institute of Medicine, first meeting of the Advisory Committee to the Editors ACE (March 2013)
- Harvard Global Health Institute, consultation on policy measures to reduce incidence of non-communicable diseases (July 2013)
- Institute of Medicine, systems strengthening meeting (September 2013)
- Center for Disease Dynamics, Economics, and Policy (Quality and Uptake meeting September 2013,

reproductive and maternal health volume consultation November 2013)

- National Cancer Institute cancer consultation (November 2013)
- Union for International Cancer Control cancer consultation (November 2013, December 2014)

Carol Levin provided outstanding governance for cost and cost-effectiveness analysis. Stéphane Verguet added invaluable guidance in applying and improving the extended cost-effectiveness analysis method. Shane Murphy, Zachary Olson, Elizabeth Brouwer, and Kristen Danforth provided exceptional research assistance and analytic assistance. Brianne Adderley ably managed the budget and project processes. The efforts of these individuals were absolutely critical to producing this series and we are thankful for their commitment.

Volume and Series Editors

VOLUME EDITORS

Hellen Gelband is Associate Director for Policy at the Center for Disease Dynamics, Economics & Policy (CDDEP). Her work spans infectious disease, particularly malaria and antibiotic resistance, and noncommunicable disease policy, mainly in low- and middle-income countries. Before joining CDDEP, then Resources for the Future, she conducted policy studies at the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations.

Prabhat Jha is the founding director of the Centre for Global Health Research at St. Michael's Hospital and holds Endowed and Canada Research Chairs in Global Health in the Dalla Lana School of Public Health at the University of Toronto. He is lead investigator of the Million Death Study in India, which quantifies the causes of death and key risk factors in over two million homes over a 14-year period. He is also Scientific Director of the Statistical Alliance for Vital Events, which aims to expand reliable measurement of causes of death worldwide. His research includes the epidemiology and economics of tobacco control worldwide.

Rengaswamy Sankaranarayanan is head of the Early Detection and Prevention Section and the Screening Group at the World Health Organization's International Agency for Research on Cancer (IARC) in Lyon, France. He was trained in radiation oncology at the University of Pittsburgh and the University of Cambridge. He is an expert in evaluating early detection strategies and has conducted trials of screening interventions for cervical, oral, and breast cancers in a number of low- and

middle-income countries. Aided by collaborative relationships with other international and national organizations and individual researchers, he provides technical assistance to countries developing public health policies that include cancer. His manuals on early detection of cervical cancer have been translated into several languages, including Chinese, French, Hindi, Portuguese, Spanish and Turkish, and others.

Susan Horton is Professor at the University of Waterloo and holds the Centre for International Governance Innovation (CIGI) Chair in Global Health Economics in the Balsillie School of International Affairs there. She has consulted for the World Bank, the Asian Development Bank, several United Nations agencies, and the International Development Research Centre, among others in work carried out in over 20 low- and middle-income countries. She led the work on nutrition for the Copenhagen Consensus in 2008, when micronutrients were ranked as the top development priority. She has served as associate provost of graduate studies at the University of Waterloo, vice-president academic at Wilfrid Laurier University in Waterloo, and interim dean at the University of Toronto at Scarborough.

SERIES EDITORS

Dean T. Jamison

Dean Jamison is a Senior Fellow in Global Health Sciences at the University of California, San Francisco, and an Emeritus Professor of Global Health at the University of Washington. He previously held academic appointments at Harvard University and the

University of California, Los Angeles; he was an economist on the staff of the World Bank, where he was lead author of the World Bank's *World Development Report 1993: Investing in Health*. He was lead editor of DCP2. He holds a PhD in economics from Harvard University and is an elected member of the Institute of Medicine of the U.S. National Academy of Sciences. He recently served as Co-Chair and Study Director of The Lancet's Commission on Investing in Health.

Rachel Nugent

Rachel Nugent is a Research Associate Professor in the Department of Global Health at the University of Washington. She was formerly Deputy Director of Global Health at the Center for Global Development, Director of Health and Economics at the Population Reference Bureau, Program Director of Health and Economics Programs at the Fogarty International Center of the National Institutes of Health, and senior economist at the Food and Agriculture Organization of the United Nations. From 1991–97, she was associate professor and department chair in economics at Pacific Lutheran University. She has advised the World Health Organization, the U.S. government, and nonprofit organizations on the economics and policy environment of noncommunicable diseases.

Hellen Gelband

See the list of Volume Editors.

Susan Horton

See the list of Volume Editors.

Prabhat Jha

See the list of Volume Editors.

Ramanan Laxminarayan

Ramanan Laxminarayan is Vice President for Research and Policy at the Public Health Foundation of India, and he directs the Center for Disease Dynamics, Economics & Policy in Washington, D.C., and New Delhi. His research deals with the integration of epidemiological models of infectious diseases and drug resistance into the economic analysis of public health problems. He was one of the key architects of the Affordable Medicines Facility for malaria, a novel financing mechanism to improve access and delay resistance to antimalarial drugs. In 2012, he created the Immunization Technical Support Unit in India, which has been credited with improving immunization coverage in the country. He teaches at Princeton University.

Contributors

Isaac F. Adewole

University of Ibadan, Ibadan, Nigeria

Hemantha Amarasinghe

Institute of Oral Health, Maharagama, Sri Lanka

Benjamin O. Anderson

Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States

Federico G. Antillon

Universidad Francisco Marroquin, Guatemala City, Guatemala

Samira Asma

Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Rifat Atun

Harvard University, Cambridge, Massachusetts, United States

Rajendra A. Badwe

Tata Memorial Centre, Mumbai, India

Freddie Bray

International Agency for Research on Cancer, Lyon, France

Frank J. Chaloupka

University of Illinois at Chicago, Chicago, Illinois, United States

Ann Chao

National Cancer Institute, Bethesda, Maryland, United States

Chien-Jen Chen

National Taiwan University, Taipei, Taiwan, China

Wendong Chen

University of Toronto, Toronto, Canada

James Cleary

University of Wisconsin, Madison, Wisconsin, United States

Anil D'Cruz

Tata Memorial Hospital, Mumbai, India

Anna J. Dare

Centre for Global Health Research, St. Michael's Hospital, University of Toronto, Toronto, Canada

Lynette Denny

University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa

Craig Earle

Cancer Care Ontario, Ontario Institute for Cancer Research, University of Toronto, Toronto, Canada

Silvia Franceschi

International Agency for Research on Cancer, Lyon, France

Cindy L. Gauvreau

Centre for Global Health Research, St. Michael's Hospital, University of Toronto, Toronto, Canada

Hellen Gelband

Center for Disease Dynamics, Economics & Policy, Washington, DC, United States

Ophira M. Ginsburg

Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; BRAC University, Dhaka, Bangladesh

Mary K. Gospodarowicz
Princess Margaret Cancer Centre, Toronto, Canada

Thomas Gross
National Cancer Institute, Bethesda, Maryland,
United States

Prakash C. Gupta
Healis Sehksaria Institute for Public Health, Mumbai,
India

Sumit Gupta
Toronto Hospital for Sick Children, Toronto, Canada

Sir Andrew Hall
International Agency for Research on Cancer, Lyon,
France

Mhamed Harif
CHU Mohammed VI, Marrakesh, Morocco

Rolando Herrero
International Agency for Research on Cancer, Lyon, France

Susan Horton
University of Waterloo, Waterloo, Ontario, Canada

Scott C. Howard
University of Tennessee Health Sciences Center,
Memphis, Tennessee, United States

Stephen P. Hunger
Children's Hospital of Philadelphia, Philadelphia,
Pennsylvania, United States

Andre Ilbawi
MD Anderson Cancer Center, Houston, Texas,
United States

Trijn Israels
Academisch Medisch Centrum, Amsterdam, the
Netherlands

David A. Jaffray
Princess Margaret Cancer Centre, TECHNIA Institute,
Toronto, Ontario

Dean T. Jamison
University of California, San Francisco, and University
of Washington, Seattle, Washington, United States

Prabhat Jha
Centre for Global Health Research, St. Michael's
Hospital, Dalla Lana School of Public Health,
University of Toronto, Toronto, Canada

Newell Johnson
Griffith University, Gold Coast, Australia

Jamal Khader
King Hussein Cancer Center, Amman, Jordan

Jane J. Kim
Harvard University, Cambridge, Massachusetts,
United States

Felicia Knaul
Miami Institute for the Americas, and Miller School of
Medicine, University of Miami, Florida, United States

Carol Levin
University of Washington, Seattle, Washington,
United States

Joseph Lipscomb
Emory University, Atlanta, Georgia, United States

W. Thomas London
Fox Chase Cancer Center, Philadelphia, Pennsylvania,
United States

Mary MacLennan
Centre for Global Health Research, St. Michael's
Hospital, University of Toronto, Toronto, Canada

Katherine A. McGlynn
National Cancer Institute, Bethesda, Maryland,
United States

Monika L. Metzger
St. Jude Children's Research Hospital, Memphis,
Tennessee, United States

Raul H. Murillo
National Cancer Institute of Colombia, Bogotá,
Colombia

Zachary Olson
University of Washington, Seattle, Washington,
United States

Sherif Omar
Cairo University, Cairo, Arab Republic of Egypt

Krishna Palipudi
Centers for Disease Control and Prevention, Atlanta,
Georgia, United States

C. S. Pramesh
Tata Memorial Centre, Mumbai, India

You-Lin Qiao
Cancer Hospital, Chinese Academy of Medical Sciences,
Peking Union Medical College, Beijing, China

Linda Rabeneck
Cancer Care Ontario, University of Toronto, Toronto,
Canada

Preetha Rajaraman
National Cancer Institute, Bethesda, Maryland,
United States

Kunnambath Ramadas

Regional Cancer Centre, Trivandrum, India

Chinthanie Ramasundarahettige

Centre for Global Health Research, St. Michael's Hospital, University of Toronto, Toronto, Canada

Timothy Rebbeck

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Carlos Rodriguez-Galindo

Harvard University, Cambridge, Massachusetts, United States

Rengaswamy Sankaranarayanan

International Agency for Research on Cancer, Lyon, France

Monisha Sharma

University of Washington, Seattle, Washington, United States

Ju-Fang Shi

Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Isabelle Soerjomataram

International Agency for Research on Cancer, Lyon, France

Lisa Stevens

National Cancer Institute, Bethesda, Maryland, United States

Sujha Subramanian

RTI International, Waltham, Massachusetts, United States

Richard Sullivan

Kings College London, King's Health Partners, London, United Kingdom

Terrence Sullivan

University of Toronto, Canadian Partnership Against Cancer, Toronto, Canada

David B. Thomas

Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States

Edward L. Trimble

National Cancer Institute, Bethesda, Maryland, United States

Joann Trypuc

Princess Margaret Cancer Centre, Toronto, Canada

Stéphane Verguet

Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States

Judith Wagner

Independent economic consultant, Bethesda, Maryland, United States

Shao-Ming Wang

Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Christopher P. Wild

International Agency for Research on Cancer, Lyon, France

Pooja Yerramilli

Harvard Global Equity Initiative, Harvard University, Cambridge, Massachusetts, United States

Cheng-Har Yip

University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Ayda Yurekli

Independent economist, Ithaca, New York, United States

Witold Zatoński

Maria Skłodowska-Curie Cancer Centre, Warsaw, Poland

Ann G. Zauber

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Fang-Hui Zhao

Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing, China

Advisory Committee to the Editors

Anne Mills, Chair

Professor, London School of Hygiene & Tropical Medicine, London, United Kingdom

Olusoji Adeyi

Director, Health, Nutrition and Population Global Practice, World Bank, Washington, DC, United States

Kesetebirhan Admasu

Minister of Health, Addis Ababa, Ethiopia

George Alleyne

Director Emeritus, Pan American Health Organization, Washington, DC, United States

Ala Alwan

Director, World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Arab Republic of Egypt

Rifat Atun

Professor, Global Health Systems, Harvard University, Boston, Massachusetts, United States

Zulfiqar Bhutta

Chair, Division of Women and Child Health, Aga Khan University Hospital, Karachi, Pakistan

Agnes Binagwaho

Minister of Health, Kigali, Rwanda

Mark Blecher

Senior Health Advisor, South Africa Treasury Department, Cape Town, South Africa

Patricia Garcia

Dean, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru

Roger Glass

Director, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States

Amanda Glassman

Director, Global Health Policy, Center for Global Development, Washington, DC, United States

Glenda Gray

Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Demissie Habte

Chair of Board of Trustees, International Clinical Epidemiological Network, Addis Ababa, Ethiopia

Richard Horton

Editor, *The Lancet*, London, United Kingdom

Edward Kirumira

Dean, Faculty of Social Sciences, Makerere University, Kampala, Uganda

Peter Lachmann

Professor, University of Cambridge, Cambridge, United Kingdom

Lai Meng Looi

Professor, University of Malaya, Kuala Lumpur, Malaysia

Adel Mahmoud

Senior Molecular Biologist, Princeton University, Princeton, New Jersey, United States

Anthony Measham

World Bank (retired)

Carol Medlin

Children's Investment Fund Foundation, London,
United Kingdom

Alvaro Moncayo

Researcher, Universidad de los Andes, Bogotá, Colombia

Jaime Montoya

Executive Director, Philippine Council for Health
Research and Development, Taguig City, the Philippines

Ole Norheim

Professor, University of Bergen, Bergen, Norway

Folashade Omokhodion

Professor, University College Hospital, Ibadan, Nigeria

Toby Ord

President, Giving What We Can, Oxford, United Kingdom

K. Srinath Reddy

President, Public Health Foundation of India, New
Delhi, India

Sevkat Ruacan

Dean, Koc University School of Medicine, Istanbul, Turkey

Jaime Sepúlveda

Executive Director, Global Health Sciences, University
of California, San Francisco, California, United States

Richard Skolnik

Lecturer, Health Policy Department, Yale School
of Public Health, New Haven, Connecticut,
United States

Stephen Tollman

Professor, University of Witwatersrand, Johannesburg,
South Africa

Jürgen Unutzer

Professor, Department of Psychiatry, University of
Washington, Seattle, Washington, United States

Damian Walker

Senior Program Officer, Bill & Melinda Gates
Foundation, Seattle, Washington, United States

Ngairé Woods

Director, Global Economic Governance Program,
Oxford University, Oxford, United Kingdom

Nopadol Wora-Urai

Professor, Department of Surgery, Phramongkutklo
Hospital, Bangkok, Thailand

Kun Zhao

Researcher, China National Health Development
Research Center, Beijing, China

Reviewers

Nicolas Andre, MD, PhD

Pediatric Oncology, Children's Hospital of La Timone, AP-HM Marseille, France

Ronald D. Barr, MD

Professor of Pediatrics, Pathology, and Medicine, McMaster University, Hamilton, Ontario, Canada

Nazmi Bilir, MD

Professor of Public Health, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Miguela A. Caniza, MD

Associate Member, Director of Infectious Diseases, International Outreach, Department of Infectious Diseases, International Outreach Program, St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Phaik-Leng Cheah, MBBS, MRC Path, FRC Path, MPath, MD

Professor, Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Maria Paula Curado, MD, PhD

Senior Researcher, International Prevention Research Institute, and Epidemiologist, Accamargo Cancer Center, International Research Center, Sao Paulo, Brasil

Henry Ddungu, MD, consultant

Uganda Cancer Institute, Kampala, Uganda

Nagi S. El Saghir, MD, FACP

Professor of Clinical Medicine, Director, Breast Center of Excellence, NK Basile Cancer Institute, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Dan Greenberg, PhD

Associate Professor and Chairman, Department of Health Systems Management, Guilford Glazer Faculty of Business Management & Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel

Raymond Hutubessy, PhD

Senior Health Economist, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland

M. Tezer Kutluk, MD, PhD

Professor of Pediatrics and Pediatric Oncologist, Hacettepe University Cancer Institute, Ankara, Turkey

Cédric Mahé, PhD

Senior Director, Global Epidemiology, Sanofi Pasteur, Lyon, France

Donald Maxwell Parkin, MD, PhD

Senior Epidemiologist, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

Aloka Pathirana MS, FRCS (Eng), FRCS (Edin)

Professor in Surgery, University of Sri Jayewardenepura, Nugegoda, Sri Lanka

Sevket Ruacan, MD

Professor of Pathology, Koc University School of Medicine, Istanbul, Turkey

Vikash Sewram, PhD (Medicine, Chemistry, and Physiology), MPH (Cancer Epidemiology), PhD (Public Health)

Director, African Cancer Institute, Stellenbosch University, Stellenbosch, South Africa

Frank A. Sloan, PhD

J. Alexander McMahon Professor of Health Policy and Management and Professor of Economics, Duke University, Durham, North Carolina, United States

Verna Dnk Vanderpuye, MBCHB, FWACS

Consultant Radiation and Clinical Oncologist, Department of Radiation Oncology, Korle Bu Teaching Hospital, Accra, Ghana

Katsuri Warnakulasuriya, Oral Med BDS, FDSRCS, PhD, Dip, DSc

Professor of Oral Medicine and Experimental Oral Pathology, King's College London, London, United Kingdom

Sidney J. Winawer, MD

Paul Sherlock Chair in Medicine, Gastroenterology and Nutrition Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Professor of Medicine, Weill Medical College, Cornell University, Ithaca, New York, United States

Cheng-Har Yip, MBBS, FRCSEd, FRCS

Consultant breast surgeon, Breast Centre, Sime Darby Medical Centre, Selangor, Malaysia

Index

Boxes, figures, maps, notes, and tables are indicated by b, f, m, n, and t respectively.

A

- abandonment of therapy
 - for breast cancer, 266, 292
 - for childhood cancer, 124, 125, 125*t*, 126–27*b*, 127, 130, 205, 205*b*, 291
 - due to expense, 282
- Abascal, W., 189
- accreditation programs, 125, 195, 199, 200, 203, 207*n*10, 244
- acute lymphoblastic leukemia (ALL). *See* leukemia
- acute promyelocytic leukemia (APL), 126*b*
- ADA (American Dental Association), 91
- Adami, H., 215
- Adewole, Isaac F., 223
- adjuvant treatment considerations for surgery, 230–31
- advertising of cigarettes, 185, 189
- affordability of cancer services, 15. *See also* catastrophic health expenditures
 - abandonment of therapy due to inability to afford, 127
 - anti-HBV drugs, 158
 - anti-HCV drugs, 156
- Afghanistan, radiation therapy in, 265
- aflatoxins, 11, 150, 151, 153, 156–57, 159
- Africa. *See also specific regions and countries*
 - cervical cancer prevention approaches in, 80
 - types of cancer in, 29
- AHOPCA (Central American Association of Pediatric Hematology Oncology), 130
- air pollution, 12, 38
- alcohol consumption
 - binge drinking, 157
 - liver cancer and, 153–54, 157
 - oral cancer and, 85, 87, 89
 - as risk factor, 37
- Algeria, cervical cancer in, 71
- ALL (acute lymphoblastic leukemia). *See* leukemia
- Amarasinghe, Hemantha, 85
- American Board of Internal Medicine’s Choosing Wisely campaign, 212
- American Cancer Society Cancer Prevention Studies, 254
- American Dental Association (ADA), 91
- American Pain Society, 166
- American Society of Clinical Oncology, 111, 212
- AMPATH Program (U.S.), 245
- Anderson, Benjamin O., 45, 216, 223, 263, 268
- anesthesia, administration of, 137–38, 224, 226
- Antillon, Federico G., 121
- antiretroviral therapy, 73, 156
- antiviral therapy for HBV and HCV, 155–56, 158, 159, 160
- APL (acute promyelocytic leukemia), 126*b*
- areca nut. *See* nut chewing
- Argentina
 - colorectal cancer in, 11, 108
 - tobacco control, compared to Uruguay, 189
- aromatase inhibitor (AI), 12*b*, 54, 60
- asbestos exposure, 12, 38
- Asia. *See also specific regions and countries*
 - breast cancer in, 216
 - cervical cancer in, 71, 71*m*
 - childhood cancer in, 121
 - health insurance coverage in, 289
 - liver cancer in, 147, 150
 - oral cancer in, 85, 87
 - types of cancer in, 29

- Asian Development Bank, 188
- Asma, Samira, 175
- Atun, Rifat, 281, 284
- Australia/New Zealand
- cancer registries in, 266
 - cigarettes in
 - plain packaging of, 185, 189
 - tax rates, 184
 - cost-effectiveness study in, 267
 - lung cancer in, 177
 - oral cancer in, 88
 - reporting system for HPV infection and vaccinations in, 258
- Austria, cervical cancer screening in, 74
- Axios Healthcare Development, 78
- B**
- Badwe, Rajendra A., 223
- Baltussen, R. M., 59, 216
- Bamako Global Ministerial Forum on Research in Health (2008), 249
- Call to Action for Research on Health, 249, 250*b*, 256
- Bangladesh
- cervical cancer in, 71, 74
 - costs of cancer treatments in, 7, 236
 - smoking in, 178, 180
- Belarus, oral cancer in, 85
- benefits of cancer control, 17. *See also* cost-effectiveness “best buys”
- in cancer services, 8
 - in research, 259–60
- betel nut. *See* nut chewing, as oral cancer risk
- bevacizumab, 13
- Bhakta, N., 138–39
- BHGI. *See* Breast Health Global Initiative
- Bhutan, HPV vaccination in, 78
- Bill & Melinda Gates Foundation, 189
- binge drinking, 157
- biobanks and biological resource centers, 252–53
- biopsy procedures, 54, 63, 227–28. *See also* tissue sampling
- biostatisticians, 257
- bladder cancer
- radiation therapy for, 240
 - schistosomiasis and, 12
- blood donations/transfusions and HCV risk, 153, 155, 158
- Bloomberg Philanthropies, 189
- Bolivia, HPV vaccination in, 78
- bone marrow transplantation, 129, 197*b*, 204, 240
- B. P. Koirala Memorial Cancer Hospital (Nepal), 206*b*
- brachytherapy, 241
- brain cancer
- incidence and death rates, 28*f*
 - radiation therapy for, 240
 - underdiagnosis of childhood brain tumors, 121
- Bray, Freddie, 23
- Brazil
- breast cancer treatment in, 60
 - childhood cancer in
 - cost-effectiveness of treatment, 139
 - mortality rates, 123
 - treatment, 127*b*
 - colorectal cancer incidence rates in, 103
 - costs of intervention packages in, 13, 277
 - oral cancer in, 85
 - percent of total health spending to cancer control in, 15
 - radiation therapy in, 245
 - smoking in, 180
 - knowledge of health information, 184
 - tobacco use in, 10
- breast cancer, 45–68. *See also* Breast Health Global Initiative
- abandonment of therapy, 266, 292
 - access to diagnostic and treatment facilities, 225
 - assessment of local situation, 57–59
 - social and cultural barriers, 58
 - target group identification, 58–59
 - breast awareness education, 50*t*, 52, 215
 - breast self-examination, 52, 216
 - chemotherapy, 11, 12*b*, 54–55, 55–56*t*, 275
 - clinical breast examination (CBE), 51–52, 60, 63, 215–16, 235, 266, 277
 - clinical evaluation, 53–54
 - clinic-based cluster randomized trial, 62–63
 - combination screening-treatment interventions, 60–61
 - comparison of modalities, 61
 - cost-effectiveness of interventions, 13, 13*f*, 59–61, 268, 269–70*t*
 - dedicated cancer center (Egypt), 206*b*
 - diagnosis, treatment, and patient triage, 63
 - diagnosis guidelines, 53–54, 53*t*
 - diagnostic imaging, 54
 - disparities in global outcomes, 45–47
 - early-stage treatment of, 8, 11, 29, 60
 - cost-effectiveness of, 13, 13*f*
 - costs of, 14*t*
 - early detection, 45, 47, 49, 50*t*, 60
 - in LMICs, 12*b*
 - scaling up, 16
 - economic analyses and future of breast health care in LMICs, 63–64
 - estrogen receptor protein, testing for, 11, 12*b*
 - field studies, 61–63

- by geographical region, 29
 - high-risk screening, 212
 - incidence and death rates, 6*t*, 8*f*, 27–29, 28*f*, 45, 46*m*, 215
 - disproportionate death rates of the young, 45
 - by income group, 31*f*, 47–48*f*, 224*f*
 - transitions in low- and middle-income countries, 29–32
 - intervention packages, 9*t*
 - literature review, 59–60
 - mammographic screening. *See* mammograms
 - overdiagnosis concerns, 213, 215
 - population-based randomized trial, 62
 - radiation therapy for, 11, 54, 55–56*t*, 60, 240
 - rate of curing, 4*b*
 - resource limitations, need for guidelines to address, 48–49
 - risk factors and risk reduction strategies, 47–48
 - screening for, 10–11, 212, 215–16
 - cost-effectiveness of, 13*f*
 - gender inequity as issue, 214
 - HIV-positive women, 219
 - maternal or reproductive health policy as umbrella for, 219
 - priority in LMICs, 218
 - surgery, 54, 223, 226, 228, 229*t*, 230
 - survivor groups, formation of, 58, 58*f*
 - systemic pharmacotherapy, 54–57
 - temporal trends in stage of disease, 61–62
 - tissue sampling, 54, 63
 - treatment guidelines, 54–57, 55–56*t*
 - tumor markers, 54
 - Breast Health Global Initiative (BHGI)
 - design of, 48–49
 - early detection guidelines, 49–57, 50*t*
 - effectiveness of, 267
 - evidence-based, resource-stratified approach, 216
 - Ghana-Norway partnership as part of, 199
 - guidelines developed by, 12*b*, 198, 218
 - implementation, 57–59
 - resource levels, 49*b*, 263–64
 - Bretthauer, M., 215
 - British doctors, cohort study of, 254
 - British Royal College of Physicians, 185
 - burden of cancer, 23–44. *See also specific types of cancer*
 - alcohol consumption and, 37
 - asbestos exposure and, 38
 - compared to other noncommunicable diseases, 24, 24*f*
 - diet and, 37–38
 - diversity of cancer by type and geographical region, 29
 - environmental factors, 38
 - hormonal and reproductive factors, 38
 - HPVs and hepatitis B and C viruses and, 36–37
 - by income group, 27–29, 31, 31–35*f*
 - infections, cancers associated with, 36–37, 37*f*
 - key indicators of, 24–27
 - incidence, 25
 - income as proxy for human development, 26
 - mortality, 25–26
 - proportion of burden attributable to risk factors, 26–27
 - obesity and, 37–38
 - occupational risk factors, 38
 - overview, 6–7, 6*t*, 8*f*, 8*t*, 17, 23–24
 - physical activity, lack of, 38
 - projected (2030), 9*t*, 17, 31–32, 36*f*
 - risk factors, 33–34
 - sun exposure and skin cancer, 38
 - surgically treatable cancers in LMICs, 224, 224*f*
 - surveillance mechanisms, need for, 39–40
 - tobacco-related cancer, 32, 34–36
 - transitions of various types of cancers, 23, 29–32
 - Burkitt, Denis, 134
 - Burkitt lymphoma, 11, 123, 129*t*, 134–37, 136*t*
- ## C
- Cambodia
 - cervical cancer in, 71
 - HPV vaccination in, 78
 - liver fluke infection in, 154
 - Cameroon
 - costs of cancer treatments in, 7, 236
 - HPV vaccination in, 78
 - Canada
 - Canadian National Breast Screening Study, 215
 - Cancer Care Ontario's Program in Evidence-Based Care, 198
 - childhood leukemia in, 122
 - colorectal screening program (ColonCancerCheck) in, 108
 - liver cancer, cost of treatment in, 159
 - radiation therapy in, 245
 - smoking in
 - excise tax increases, 184
 - inverse relationship of consumption and price, 183, 183*f*
 - smuggling and black market sales of cigarettes, 187
 - taxation to finance universal health coverage in, 284
 - Victoria Hospice (Victoria, British Columbia), 206*b*
 - cancer awareness
 - breast awareness education, 50*t*, 52, 215
 - cultural practices and, 225
 - public awareness of, 16, 255

- Cancer Care Ontario's Program in Evidence-Based Care, 198
- cancer death rates. *See also specific types of cancer*
 decreases (2000 to 2010), 6, 8t, 17
 in high-income countries (HICs), 2–3m, 6t, 8f
 as key indicator of burden of cancer, 25–26
 in low- and middle-income countries (LMICs),
 2–3m, 6t, 8f
 projected (2030), 9t, 17, 245
 by region, 27f
- cancer incidence. *See also specific types of cancer*
 as key indicator of burden of cancer, 25, 27f
 most common cancers by gender, 30m
 projected (2030), 36f
 registries compiling information on, 251
- Cancer Incidence in Five Continents* (IARC), 25, 57, 266
- Cancer Intervention and Surveillance Modeling
 Network (CISNET), 111
- cancer registries. *See* registries
- cancer research. *See* research support
- cancer screening, 211–22. *See also specific types of cancer*
 care pathway for positive results, development of, 214
 cost-effectiveness of, 214, 275–76
 criteria for, 213
 diagonal approach to, 218–19
 effectiveness of, 10–11, 275–76
 ethical considerations, 214–15
 false-positive screening tests, 213
 follow-up strategies, 214
 high-risk screening, 212
 infrastructure, education, and advocacy, 213–14
 innovation, role of, 218
 lead-time bias and, 212
 length bias and, 213
 opportunistic vs. organized screening, 108, 211–12,
 266, 277
 organized screening requirements, 108, 213–15
 overdiagnosis concerns, 213, 215
 overview, 211
 policy considerations, 219
 population-based screening, 212
 priorities in LMICs, 218
 structural obstacles to, 214
 target age range of, 212
 Wilson-Junger criteria for, 213, 213b
- cancer services for comprehensive cancer center. *See*
 comprehensive cancer centers
- cancer surveillance systems. *See* surveillance systems
- cancer survival rates, 291. *See also specific types of cancer*
 in high-income countries (HICs), 1, 6t
 in low- and middle-income countries (LMICs), 6t
- Canfell, K. H., 296
- capacity building. *See also* scaling up
 radiation therapy and, 275
 research support and, 250b
 surgery and, 232–35, 275
- case-control studies, 253
- catastrophic health expenditures, 7, 282, 284, 290
- Centers for Disease Control and Prevention (U.S.), 252
- Central American Association of Pediatric Hematology
 Oncology (AHOPCA), 130
- Central Asia
 alcohol consumption in, 157
 cervical cancer in, 69
 HPV vaccination in, 79
 liver cancer in, 149
- Central Europe
 colorectal cancer in, 102
 liver cancer in, 149
 oral cancer in, 88
- cervical cancer, 69–84
 burden of, 69–71, 216, 295, 300–301
 global, 69, 70f
 regional, 71, 71m, 72f
 chemotherapy, 11, 78, 275
 cost-effectiveness of interventions, 8, 13, 78–79, 81,
 217, 268, 271t
 cytology classification and terminology, 72–73,
 297–98
 early-stage treatment of, 8, 11
 scaling up, 16
 epidemiology and biology research, 257
 by geographical region, 29
 HIV and, 73, 219
 HPV infection, integrated research on link to,
 257–59, 258–59b. *See also* HPV (human
 papillomavirus) infection
 HPV vaccination programs for. *See* HPV (human
 papillomavirus) vaccination
 incidence and death rates, 6t, 8f, 27–29, 28f, 69,
 215, 216
 by income group, 34f, 72f, 224f
 median age at death, 71
 trends in, 29
 integrated research exemplar, 257–59
 natural history of, 72
 overview, 69
 Pap smears and, 69, 73, 74, 216
 radiation therapy for, 11, 78, 240
 rate of curing, 4b
 research support for, 259–60
 screening for, 10, 69, 73–77, 74t, 216–17
 case study of upscaling VIA, 75
 combined HPV vaccination and screening,
 80–81, 217
 cost-effectiveness of, 80

- cryotherapy (screen-and-treat approach), 217
 - gender inequity as issue, 214
 - HIV-positive women, 219
 - HPV testing, 75–77
 - maternal or reproductive health policy
 - as umbrella for, 219
 - priority in LMICs, 218
 - self-collection by women, 76
 - target age for, 212
 - triage of positive HPV tests, 76–77
 - visual inspection with acetic acid (VIA), 74–75, 217, 266, 277, 297–98
- surgery, 228, 229*t*
- treatment of, 9*t*, 78
 - costs of, 14*t*
- cetuximab, 13
- Chaloupka, Frank. J., 175
- Chao, Ann, 249
- chemotherapy
 - breast cancer, 11, 12*b*, 54–55, 55–56*t*, 275
 - Burkitt lymphoma, 135–37
 - cervical cancer, 11, 78, 275
 - childhood cancer, 124, 125*t*, 126, 128, 129*t*
 - colorectal cancer, 110, 111, 112, 114, 275
 - comprehensive cancer center services, 200, 231
 - in conjunction with radiation therapy, 240, 243
 - in conjunction with surgery, 231
 - health insurance coverage and, 290
 - Hodgkin lymphoma, 131–32, 132*t*
 - oral cancer, 94, 275
 - retinoblastoma, 138
 - scaling up, 16, 275
 - Wilms tumor, 133–34
- Chen, Chien-Jen, 147
- Chen, Wendong, 147
- Chennai Prospective Study, 254
- childhood cancer, 121–46. *See also* leukemia
 - abandonment of therapy, 124, 125, 125*t*, 126–27*b*, 127, 127*b*, 130, 205, 205*b*, 291
 - achievability of cure, 123
 - burden in LMICs of, 121–23
 - Burkitt lymphoma, 11, 123, 129*t*, 134–37, 136*t*
 - characteristics of most common childhood cancers, 129*t*
 - chemotherapy, 124, 125*t*, 126, 128, 129*t*
 - cost-effectiveness of interventions, 13, 13*f*, 138–40, 139–40*f*, 268, 275–76*t*, 277
 - costs of interventions, 14*t*
 - future directions for progress, 140
 - in HICs, 121, 126
 - Hodgkin lymphoma, 129*t*, 131–33, 132*t*, 240
 - incidence rates, 121
 - inclusion in cancer registries, 121, 122*f*
 - ineffectiveness of prevention and screening, 123
 - International Incidence of Childhood Cancer* (IARC), 123
 - in LMICs, 123, 125*t*, 127, 128, 139
 - locally adapted treatment protocols, 126–27, 139
 - Mexican national health insurance coverage of, 1
 - mortality rates, 123
 - outcome evaluation, 127–28
 - rate of curing, 4*b*
 - retinoblastoma, 137–38
 - scaling up, 277
 - spillover effect from pediatric to adult oncology, 123
 - treatment of, 11, 123–25
 - dedicated centers, 123–24, 124*t*, 128
 - infrastructure needed in LMICs, 125*t*
 - principles of, 126–28
 - specific cancers, 128–38
 - treatment facilities, organization of, 9*t*, 16, 125*t*
 - twining programs, 124–25, 130, 140, 266
 - underdiagnosis of childhood brain tumors, 121
 - Wilms tumor, 11, 126, 133–34, 133*t*, 135*t*
- Children's Oncology Group in North America, 133
- Chile
 - opioids for pain relief in, 169
 - training of health care professionals in, 204
- China
 - air pollution in, 38
 - breast cancer in, 52, 60
 - cervical cancer in
 - burden of, 301
 - screening program, 295–96
 - childhood cancer treatment in, 125
 - acute lymphoblastic leukemia (ALL), 128, 130–31
 - chronic lung disease in, 178
 - colorectal cancer in, 103, 111
 - cost-effectiveness of HPV vaccination in, 295–305. *See also* HPV vaccination
 - costs of intervention packages in, 277
 - dietary changes in, 150, 156
 - HBV infection in, 151
 - HBV vaccination in, 150, 155, 158
 - HCV infection in, 151
 - HPV vaccination in, 295–305. *See also* HPV vaccination
 - liver cancer in, 149, 150
 - liver fluke infection in, 154
 - national health insurance in, 284, 285*t*, 289, 290, 292
 - cancer surgery coverage, 7
 - co-payments, 291
 - fee-for-service basis, 292
 - opioid accessibility in, 170
 - oral cancer in, 88, 94

- percent of total health spending to cancer
 - control in, 15
 - smoking in, 179, 180
 - affordability, 182
 - implications of tobacco taxation, 188
 - knowledge of health information, 184
 - male smoking prevalence, 30, 35, 177
 - price elasticity, 181
 - related cancer deaths in, 177
 - starting age of men, 178
 - stomach cancer in, 218
 - types of cancer in, 29
- China Kadoorie Biobank, 254, 255*b*
- chronic lung disease, 178
- chronic trauma, as risk factor for oral cancer, 90
- cigarettes. *See* tobacco taxes; tobacco use
- cirrhosis, 147, 150, 151, 153
- CISNET (Cancer Intervention and Surveillance Modeling Network), 111
- Cleary, James, 165
- clinical breast examination. *See* breast cancer
- Clinton Health Access Initiative, 16
- Clonorchis sinensis*, 36
- Cochrane Collaboration, 91
- codeine, 165, 166, 168
- cohort studies, 254, 254–55*b*
- Colombia
 - breast cancer in, 62
 - childhood cancer in, 16
 - universal health care in, 284, 285*t*
 - cancer coverage, 290, 291
 - incentives to improve coverage, 292
- colonoscopy, 106–7, 217
- colorectal cancer (CRC), 101–19
 - burden of, 101–5, 217
 - chemotherapy, 110, 111, 112, 114, 275
 - cost-effectiveness of interventions, 7*b*, 13, 13*f*, 114, 217, 268, 272–73*t*
 - diagnosis of, 109
 - diet, lifestyle, and medications as risk factors for, 105, 114, 217
 - European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis* (IARC), 107, 108
 - genetic factors, 105
 - high-income countries recommendations, 116
 - high-risk screening, 212
 - incidence and death rates, 6*t*, 8*f*, 27–29, 28*f*, 101–5
 - by gender, 102*m*, 103–4*f*, 215
 - by income group, 33*f*, 103–5, 105*f*, 224*f*
 - transitions in low- and middle-income countries, 29
 - trends, 102–3
 - intervention packages, 9*t*
 - low-income countries recommendations, 114
 - middle-income countries recommendations, 115
 - overview, 101
 - physical inactivity, relationship to, 38
 - radiation therapy for, 110
 - recommendations, 114–16, 115*t*
 - research support for, 260
 - risk factors, 105
 - screening for, 11, 101, 105–9, 217
 - ColonCancerCheck (Canadian program), 108
 - colonoscopy, 106–7, 217
 - computerized tomographic colonography (CTC), 106
 - cost-effectiveness of, 11, 111–14
 - fecal DNA, 106
 - fecal immunochemical test (FIT), 105–6, 277
 - flexible sigmoidoscopy (FS), 106
 - guaiac fecal occult blood test (gFOBT), 105, 108
 - high-risk screening, 212
 - IARC guidelines, 107, 108–9
 - ICRCNS pilot program, 108
 - International Cancer Screening Network, 109
 - International Digestive Cancer Alliance, 109
 - organized vs. opportunistic screening, 108
 - performance of organized screening programs, 108
 - USMSTF guidelines, 108
 - USPSTF guidelines, 107–8
 - World Endoscopy Organization, 109
 - staging of, 109–10
 - barium enema, 109
 - computerized tomography, 109–10
 - surgery, 110, 223, 228, 230, 230*t*
 - treatment of, 110–11
 - international partnership arrangements to support in LMICs, 111
 - metastatic colorectal cancer, 110–11
- Commission on Macroeconomics and Health, 7*b*
- community health centers, 226–27, 228–30*t*
- community health workers, 200, 201, 256, 290
- community involvement, 214
- comprehensive cancer centers, 195–210
 - accreditation programs, 207*m*10
 - additional key supports, 202
 - administration and management, 201
 - affordability and domestic financing of, 15
 - cancer system components, 195–96, 196*f*
 - cancer system planning, 195
 - chemotherapy, 200, 231
 - clinical management, 197–98, 198*f*
 - clinical practice guidelines, 197–98
 - patient care plans, 197

clinical services, 198–200, 198f
 core services, 198f, 200–202
 financial systems, 202
 framework, 197–202, 198f
 global health, contribution to, 204–5
 human resources, 201
 infection control, 201–2, 207n9
 information technology and management, 201
 in LMICs, 196
 medical imaging (diagnostic radiology), 199
 office- and clinic-based ambulatory care, 199
 palliative care, 200
 pathology and laboratory medicine, 199
 pharmacy services, 201
 psychosocial support, 200
 quality assurance, 202
 quality of care with minimal resources, 202–5
 accessibility, 202
 catalyzing development of national
 systems, 203
 effectiveness, 202
 efficiency, 203
 equity, 202
 responsiveness, 202
 safety, 202
 radiation therapy, 199–200, 243
 regional cancer centers, establishment of, 203
 role in support of development of effective
 health care systems, 204
 supportive care, 200
 surgery, 199, 232
 survivorship programs, 200
 systemic cancer therapy, 200
 training of health care professionals, 203–4
 Congo, Democratic Republic of, liver cancer in, 149
 co-payments, 291
 cost-effectiveness, 13, 13f, 267–69. *See also specific
 types of cancer*
 cancer screening, 214, 275–76
 estimates of, 7b
 HPV vaccination, cost-effectiveness in China,
 295–305. *See also* HPV (human
 papillomavirus) vaccination
 methods, 267–68
 results based on level of resources,
 268–69, 268t
 studies of, 263, 267
 surgery, 235–36
 costs. *See also* affordability of cancer services;
 financing; *specific types of cancer*
 of cancer drugs, 12b
 catastrophic health expenditures, 7, 282, 284, 290
 DCP3 analysis of, 5b
 of interventions, 4b, 7b, 13–14, 14t, 277
 priority of reduction for essential intervention
 packages, 16
 of surgery, 235–36
 Council of Europe, 168
 CRC. *See* colorectal cancer
 Cuba, oral cancer in, 92, 94
 cultural practices
 breast cancer and, 58
 cancer awareness and, 225
 cancer screening and, 214
 cervical cancer and, 71
 fatalism and, 225
 surgery and, 225
 Cure4Kids, 125
 customs reform to allow for importation of health
 research components, 253, 256
 cytosine, 186
 cytotoxic regimens, 12b
 Czech Republic, oral cancer in, 87

D

Dare, Anna J., 223
 D’Cruz, Anil, 195
 death certificates, indicating smoking habits of
 deceased, 185
 death rates. *See also* cancer death rates
 top 10 causes of death worldwide, 24, 24f
 death registration systems, linking to cancer
 registration systems, 253. *See also* registries
 delayed presentation for cancer as norm in LMICs,
 213–14, 234, 282, 290
 Democratic Republic of Congo, liver cancer in, 149
 Denny, Lynette, 69, 268
 diagnosis and staging, 11. *See also specific types of
 cancer*
 role of laboratories and anatomic pathology, 252
 surgery’s diagnostic role, 227
 UICC Tumor, Nodes, Metastasis (TNM) staging
 system, 92
 diagnostic imaging
 breast cancer, 54
 comprehensive cancer center services, 199
 follow-up to positive screening test with, 214
 oral cancer and, 92
 surgery’s reliance on, 226
 diet, relationship to cancer, 37–38
 colorectal cancer, 105
 liver cancer, 150, 156
 digital mammography, 51
 Dikshit, R., 253
 disability-adjusted life years (DALYs)
 cervical cancer and, 71, 216

- cost-effectiveness and DALYs averted, 13, 214
- liver cancer and, 150
- Disease Control Priorities*
 - HPV (human papillomavirus) vaccination in
 - essential package of, 8
 - publication background of, 5*b*
- DNA testing for HPV. *See* HPV (human papillomavirus) infection
- Doll, Richard, 176
- Dominican Republic
 - childhood cancer treatment in, 130
 - universal health care in, 284, 286*t*, 289
- drug costs. *See* affordability of cancer services
- drug therapy. *See also* chemotherapy; pain relief
 - breast cancer, 55–56*t*, 55–57
 - comprehensive cancer centers, 201
 - constraints on, 265
 - as risk factor, 105
 - smoking cessation treatment, 186
 - universal health care, coverage of, 290
- Dutch Childhood Oncology Group, 130–31

E

- Earle, Craig, 101
- East Asia and Pacific
 - aflatoxins in, 153
 - HBV infection in, 151
 - HCV infection in, 155
 - liver cancer in, 147, 149
 - stomach cancer in, 218
- Eastern Europe
 - colorectal cancer in, 102
 - oral cancer in, 85, 87
 - types of cancer in, 29
- e-cigarettes, 186
- Egypt
 - breast cancer in, 206*b*
 - cervical cancer in, 71
 - Fakous Cancer Center, 206*b*
 - HCV infection in, 151, 153
 - incidence of HBV vs. HCV in, 151, 152*f*
 - liver cancer in, 149
 - National Cancer Institute, 206*b*
- endocrine therapy, 54–55, 55–56*t*
- environmental factors, 38
- epidemiologic studies, 253–57, 260
- Epstein-Barr virus, 36, 131
- Ergo, A., 283
- erythroplakia, 90
- esophagus. *See* oral cancer
- estrogen receptor protein, testing for, 11, 12*b*, 45
- ethical considerations of cancer screening, 214–15
- Ethiopia

- cervical cancer screening in, 74
- domestic funding in, 282
- opioid accessibility in, 168–69
- European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis* (IARC), 107, 108, 109
- European Medicines Agency, 258
- Europe/European Union. *See also specific regions and countries*
 - alcohol consumption in, 157
 - cancer registries in, 266
 - cervical cancer in, 69
 - HPV vaccination in, 79
 - liver cancer in, 150
 - lung cancer in, 177
 - radiation therapy in, 244
 - smoking in, 180

F

- Fakous Cancer Center (Egypt), 206*b*
- false-positive screening tests, 213
- farming practices. *See* aflatoxins
- FCTC (Framework Convention on Tobacco Control), 10, 89, 188, 189
- fee-for-service payments, 292
- fentanyl patch, 168, 169, 170
- Ferlay, J., 25
- financing, 281–94. *See also* health insurance
 - cancer care and, 15, 282–83
 - co-payments, 291
 - country approaches, 283
 - domestic funding, 282
 - need for financial protection, 282
 - out-of-pocket spending by families, 282, 290
 - overview, 281–82
 - progressive universalism, 283
 - public financing, 282, 290–91
 - research support and, 256
 - surgery and, 235–36
- Finland, ban on advertising of cigarettes in, 185
- first-level hospitals
 - intervention packages, 9*t*
 - surgery in, 227, 228*t*
- flukes. *See* liver fluke infection
- Foley, K. M., 166
- Fonseca, M., 60
- Food and Drug Administration (U.S.), 258
- food and grain storage. *See* aflatoxins
- Framework Convention on Tobacco Control (FCTC), 10, 89, 188, 189
- France
 - HCV treatment in, 156
 - liver cancer in, 149

oral cancer in, 85
smoking in
 cigarette taxes, 10, 184
 inverse relationship of consumption and price,
 183, 183*f*
 restrictions in public places, 185
Franceschi, Silvia, 147
Fred Hutchinson Cancer Research Center (Seattle,
 Washington), 205*b*
Frenk, J., 214

G

Gakidou, E., 74
Gambia, liver cancer in, 149
Gardasil Access Program, 78
gastric cancer. *See* stomach cancer
Gauvreau, Cindy L., 1, 223, 263
Gavi (The Vaccine Alliance), 10, 16, 36, 78–80, 155, 299
Gelband, Hellen, 1, 147, 165, 268, 281
gender differences
 cancer incidence and mortality by geographical
 region, 29, 215
 delay in screening for women, 214
 liver cancer, 148*m*, 149
 lung cancer, 29
 most common cancers by gender, 30*m*, 215
 oral cancer, 86*t*, 87–88*m*
 smoking and associated cancer risks, 35–36, 176,
 177*f*, 180
genetic factors
 colorectal cancer, 105
 high-risk screening and, 212
 liver cancer, 149
 oral cancer, 89–90
 retinoblastoma, 137
Georgia, opioid accessibility in, 169
Germany
 opioid accessibility in, 170
 smoking restrictions in public places in, 185
Ghana
 breast cancer screening in, 290
 cervical cancer screening in, 217
 Ghana-Norway partnership as part of Breast Health
 Global Initiative, 199
 HPV vaccination in, 78
 liver cancer in, 149
 universal health care in, 284, 286*t*, 289, 290
 taxes to finance, 292
Ginsburg, Ophira M., 211
GlaxoSmithKline, 299
Global Adult Tobacco Survey, 180, 182, 184
Global Fund for AIDS, TB and Malaria, 16
Global Initiative for Cancer Registry Development, 39

globalization
 comprehensive cancer centers, contribution to,
 204–5
 initiatives for cancer control, 16–17
 tobacco use and, 189
Global Monitoring Framework for Noncommunicable
 Diseases (WHO), 166
Global Opioid Policy Initiative (GOPI), 168, 170–71
Global Task Force on Expanded Access to Cancer Care
 and Control, 218–19
Global Task Force on Radiotherapy for Cancer
 Control, 16
Global Youth Tobacco Survey, 182
Goldie, S. J., 80, 296
Gospodarowicz, Mary K., 195, 239
Greenberg, D., 111, 267
Gross, Thomas, 249
Guatemala
 childhood cancer treatment in, 127*b*, 130, 197
 Unidad Nacional de Oncología Pediátrica
 (UNOP), 140
 opioid accessibility in, 170
Guinea
 cervical cancer in, 71
 liver cancer in, 149
Guinea-Bissau, liver cancer in, 149
Gupta, Prakash C., 175
Gupta, Sumit, 121, 205
Guyana, cervical cancer in, 71
Gwatkin, D. R., 283

H

Haiti
 domestic funding in, 282
 HPV vaccination in, 78
Hall, Andrew, 147
Harif, Mhamed, 121
HBV. *See* hepatitis B and C viruses
HCC (hepatocellular carcinoma). *See* liver cancer
HCV. *See* hepatitis B and C viruses
HDI (Human Development Index), 31, 71, 81*n*2,
 166, 226
HDV (hepatitis D virus), 149
head and neck cancers
 imaging techniques for, 198
 radiation therapy for, 240
health care professionals
 research support role of, 250, 251*b*
 screening by community care workers
 and nurses, 218
 shortage of skilled medical personnel, 232–33, 266
 training of, 203–4
health communications, 255

- health insurance
 - as constraint, 266, 282
 - coverage by population group, 284, 289
 - fee-for-service basis, 292
 - incentives, 292
 - results of coverage, 291–92
 - Seguro Popular (Mexico), 1, 125, 204, 266, 283, 284, 287*t*, 291
 - services and conditions covered, 289–90
 - universal health coverage of cancer services, 4*b*, 234, 281, 283, 284, 289
- Health Insurance Plan of Greater New York, 51
- health surveillance systems. *See* surveillance systems
- heart attack, smoking's relationship to, 178, 185, 187
- hepatitis B (HBV) and C (HCV) viruses, 154–56
 - antiviral therapy for, 155–56, 158, 159, 160
 - burden of cancer linked to, 36–37
 - liver cancer, 149–53
 - communication about, 255
 - incidence of HBV vs. HCV in, 151, 152*f*
 - prevention of HCV, 156*b*
 - screening for, 155–56
 - treatment of HBV, 155. *See also* hepatitis B vaccination
 - cost-effectiveness of, 158
 - treatment of HCV, 155–56
 - cost-effectiveness of, 158–59
- hepatitis B (HBV) vaccination, 4*b*, 154–55
 - burden of cancer and, 36
 - communication about, 255
 - cost-effectiveness of, 8, 13, 13*f*, 158, 267
 - costs of, 14*t*
 - global coverage, 10, 147
 - plasma-derived vaccine, 15
 - scaling up, 15, 149
- hepatitis D virus (HDV), 149
- hepatocellular carcinoma (HCC). *See* liver cancer
- herpes virus type 8, 36
- Herrero, Rolando, 69
- high-income countries (HICs)
 - advanced cancer treatment in, 12
 - breast cancer in, 45, 48, 215
 - Burkitt lymphoma in, 135
 - cancer death rates in, 2–3*m*, 6*t*, 8*f*, 24, 27–28, 165
 - cancer survival rates in, 1
 - cervical cancer in, 70*f*
 - childhood cancer in, 11, 121
 - colorectal cancer in, 101, 108, 116
 - cost-effectiveness of cancer interventions in, 7*b*, 268
 - HCV infection in, 155
 - high-risk screening for breast or ovarian cancer in, 212
 - liver cancer in, 150
 - lung cancer in, 29
 - palliative care in, 11, 167, 169
 - percent of total health spending to cancer control in, 15
 - prostate cancer in, 29
 - retinoblastoma in, 138
 - smoking in
 - advertising of cigarettes, ban on, 185
 - e-cigarettes, 186
 - health information and counter-advertising, 184–85
 - public places, restrictions on, 185
 - tobacco control, investment in, 189
 - tobacco excise taxes, 182–83
 - types of cancer prevalent in, 27
- Hill, A., 156
- HIV. *See also* antiretroviral therapy
 - cervical cancer and, 73
 - screening HIV-positive women for breast and cervical cancer, 219
- Hodgkin lymphoma, 129*t*, 131–33, 132*t*, 240
- Honduras
 - cervical cancer in, 71
 - childhood leukemia in, 16, 122, 197
- Hong Kong SAR
 - colorectal cancer in, 111
 - oral cancer in, 88
 - smoking risks in, 178–79
- hormonal and reproductive factors, 38
- Horton, Susan, 1, 101, 263, 281
- Hospice Africa Uganda, 168, 170
- hospice-palliative care, 167
- hospitals. *See also* comprehensive cancer centers
 - intervention packages, 9*t*
 - research role of, 250
 - surgery in, by hospital level, 227, 228*t*
 - upgrading, 16
- households, impact on, 7–8. *See also* catastrophic health expenditures
- Howard, Scott C., 121
- HPV (human papillomavirus) infection
 - burden of cancer linked to, 36–37, 69, 71, 72, 282, 300–301
 - communication about, 255
 - DNA testing for, 233, 258, 266, 267
 - future research needs, 258–59, 258–59*b*
 - integrated research establishing link to cervical cancer, 257–59
 - oral cancer and, 87, 88, 90, 218
 - screening for, 10, 75–77, 212
 - in China, 296–97
- HPV (human papillomavirus) vaccination
 - case studies of implementation, 78

- combined HPV vaccination and screening, 80–81, 217
 - communication about, 255
 - cost-effectiveness in China, 295–305
 - benefits and costs of publicly financed program, 299–301, 300*t*
 - cost assumption, 303
 - cost data sources, 299
 - delay in approving HPV vaccines, 303
 - extended cost-effectiveness analysis, 296–97
 - limitations of analysis, 303
 - model, 297, 298*t*
 - policy reform to expand present Expanded Program for Immunization, 303
 - results, 299–300, 302*t*
 - sensitivity analysis, 299, 300–301*t*
 - strategies, data, and assumptions, 297–98
 - cost-effectiveness of, 13, 13*f*, 79–80, 217, 267
 - in China, 295–305. *See also above*: cost-effectiveness in China
 - costs of, 14*t*, 282
 - in *DCP3 Cancer* essential package, 8
 - efficacy, 4*b*, 77
 - Gavi subsidy of, 36
 - national programs, 10, 69
 - public health challenges to implementing, 77
 - scaling up, 15, 217
 - universal health coverage of, 291
 - Human Development Index (HDI), 31, 71, 81*n*2, 166, 226
 - human immunodeficiency virus. *See* HIV
 - human rights, pain relief as, 165
 - Human Rights Watch, 168
 - human T-cell lymphotropic virus type 1, 36
 - Hungary, oral cancer in, 87, 88
 - Hunger, Stephen P., 121
- I**
- IAHPC (International Association for Hospice and Palliative Care), 167, 170
 - IARC. *See* International Agency for Research on Cancer
 - ICRCSN (International Colorectal Cancer Screening Network), 108, 217
 - Ilbawi, Andre, 223
 - imaging. *See* diagnostic imaging
 - implementation science, 255–56
 - as “best buy” for cancer research, 259
 - INCB (International Narcotics Control Board), 168
 - incidence. *See* cancer incidence; *specific types of cancer*
 - income as proxy for human development, 26
 - India
 - acute lymphoblastic leukemia (ALL) in, 128
 - breast cancer in, 45–47, 52, 226, 235
 - Mumbai trial, 216, 218
 - cancer death rates in, 7
 - cancer surgery costs in, 7
 - cervical cancer in, 71, 217, 258
 - childhood cancer in, 121, 122
 - chronic lung disease in, 178
 - costs of intervention packages in, 13, 282
 - guidelines adapted to local resource availability in, 198
 - HBV infection rates in, 149
 - HBV vaccination in, 158
 - HCV treatment, cost-effectiveness of, 159
 - HPV testing and reduction in cervical cancer in, 258
 - liver cancer in, 149, 150
 - Million Death Study, 39
 - National Cancer Control Program, 203–4*b*
 - National Cancer Grid, 16, 231
 - opioid accessibility in, 168, 170
 - oral cancer in, 11, 85, 89, 92, 94, 95
 - percent of total health spending to cancer control in, 15
 - radiation therapy in, 245
 - regional cancer centers in, 203–4*b*
 - retinoblastoma in, 137
 - smoking in, 178, 180
 - cigarette taxes, 10, 188
 - knowledge of health information, 184–85
 - related cancer deaths in, 178
 - surgery, private vs. public sector provision of services in, 234
 - tuberculosis in, 178
 - universal health care in, 284, 286*t*, 289, 290, 292
 - cap on payments, 292
 - co-payments, 291
 - Indonesia
 - acute lymphoblastic leukemia (ALL) in, 128
 - breast cancer detection in, 51
 - childhood cancer treatment in, 127*b*
 - smoking in, 180
 - male smoking prevalence, 30
 - WTO case on U.S. ban of clove-flavored cigarettes, 189
 - types of cancer in, 29
 - inequality in health, contribution of cancer control to reducing, 17
 - infections, cancers associated with, 36–37, 37*f*. *See also* HPV (human papillomavirus) infection
 - information technology and management, 201, 218
 - informed consent to mammographic screening, 51
 - injected drug administration and HCV infection, 151, 155, 156*b*
 - Institute for Health Metrics and Evaluation, 250
 - International Agency for Research on Cancer (IARC)
 - on alcohol as liver carcinogen, 153

- on breast self-examination, 52
 - Cancer Incidence in Five Continents*, 25, 57, 266
 - on cervical cancer screening, 73
 - on clinical breast examination, 51
 - on colorectal cancer screening, 107, 108–9
 - estimating cancer incidence and death rate, 6
 - global initiative for cancer registry, 40, 40*m*
 - GLOBOCAN, 7*b*, 25, 27, 81*n*1, 297
 - International Incidence of Childhood Cancer*, 123
 - on liver flukes, 154
 - on lung cancer in men in HICs, 177
 - on mammogram screenings, 50
 - Monographs on the Evaluation of Carcinogenic Risks to Humans*, 12
 - national cancer mortality databank of, 26
 - radiation facilities provided to Sub-Saharan Africa by, 266
 - Working Group on Cervical Cancer Screening, 73
 - International Association for Hospice and Palliative Care (IAHPC), 167, 170
 - International Association of Cancer Registries, 25
 - International Atomic Energy Agency (IAEA), 199, 244
 - Programme of Action for Cancer Therapy, 245, 267
 - International Cancer Screening Network, 109, 267
 - International Childhood Cancer Cohort Consortium, 254
 - International Classification of Diseases, 25, 26
 - International Colorectal Cancer Screening Network (ICRCNSN), 108, 217
 - International Digestive Cancer Alliance, 109
 - International Federation of Gynecology and Obstetrics, 78
 - International Narcotics Control Board (INCB), 168
 - International Network for Cancer Treatment and Research, 206*b*
 - International Observatory of End of Life Care, 167
 - international partnerships. *See also* twinning programs
 - colorectal cancer and, 111
 - effectiveness of, 266–67
 - research support, 257
 - International Society of Oncology Pharmacy Practitioners, 201
 - International Society of Pediatric Oncology (SIOP), 125
 - Abandonment of Treatment Working Group, 127
 - International Society of Radiology, 199
 - interventions. *See also specific types of cancer*
 - cost-effectiveness of, 4*b*, 7*b*, 13, 13*f*
 - diagnosis and treatment, 11
 - essential packages of, 8–13, 9*t*
 - implementation challenges for, 15–16
 - local priority conditions, 11–13
 - palliative care. *See* pain relief
 - prevention. *See* prevention strategies
 - resource requirements, 14, 14*t*
 - screening. *See* cancer screening
 - surgery. *See* surgery
 - intestinal cancer. *See* stomach cancer
 - intravenous drug users, HCV infection in, 151, 155, 156*b*
 - Iran, opioid accessibility in, 170
 - Iraq, radiation therapy in, 265
 - Ireland
 - radiation therapy in, 245
 - smoking restrictions in public places in, 185
 - Israel, liver cancer in, 150
 - Israels, Trijn, 121
 - Italy
 - HCV infection in, 151
 - incidence of HBV vs. HCV in, 151, 152*f*
- J**
- Jaffray, David A., 239
 - Jamaica
 - cervical cancer in, 71
 - opioid accessibility in, 169
 - Jamison, Dean T., 295
 - Japan
 - cancer death rates in, 24
 - quitting smoking's effect on, 178
 - smoking's effect on, 175–76, 177*f*
 - colorectal cancer screening in, 108
 - HCV infection in, 151
 - incidence of HBV vs. HCV in, 151, 152*f*
 - liver cancer in, 149
 - lung cancer in, 177
 - mammography in, 63
 - oral cancer in, 88
 - stomach cancer in, 218
 - Japan Life Span Study, 254
 - Jha, Prabhat, 1, 175
 - Johnson, Newell, 85
 - Jordan
 - childhood leukemia in, 122
 - King Hussein Cancer Foundation, 196, 196–97*b*
 - opioid accessibility in, 168
- K**
- Kalager, M., 215
 - Kaposi sarcoma, 29
 - Kenya
 - HPV vaccination in, 78
 - opioid accessibility in, 168–69
 - radiation therapy in, 245
 - Khader, Jamal, 195

- Kim, Jane J., 69, 295
- King Hussein Cancer Foundation (Jordan), 196, 196–97*b*
- Knaul, Felicia, 195, 214, 281, 284
- Korea, Republic of
- breast cancer treatment in, 60
 - colorectal cancer in, 108, 111
 - fee-for-service payments in, 292
 - liver cancer in, 149
 - liver fluke infection in, 154
 - mammograms in, 60
 - oral cancer in, 88
 - stomach cancer in, 218
 - thyroid cancer in women in, 29
- L**
- laboratories. *See also* pathology
- in comprehensive cancer centers, 199
 - constraints, 265
 - research role of, 252
- Ladner, J., 78
- Lambert, R., 114, 217
- Lan, N. H., 235
- Lancet Commission on Investing in Health, 284
- Lao People's Democratic Republic
- HPV vaccination in, 78
 - liver cancer in, 149
 - liver fluke infection in, 154
- larynx. *See* oral cancer
- Latin America and the Caribbean. *See also specific countries*
- aflatoxins in, 157
 - alcohol consumption in, 157
 - cervical cancer in, 71, 71*m*
 - health care coverage, variations in, 284, 289
 - liver cancer in, 149, 150
 - Network of National Cancer Institutions of Latin America (RINC) initiative, 245
 - oral cancer in, 85
 - radiation therapy in, 244
 - types of cancer in, 29
- lead-time bias, 212
- Lee, S., 60
- length bias, 213
- Lesotho, HPV vaccination in, 78
- leukemia
- acute lymphoblastic leukemia (ALL), 11, 127, 128–31
 - characteristics of, 129*t*
 - chemotherapy, 129–30
 - costs of treatment, 130–31, 290
 - diagnosis of, 129
 - in HICs, 128–29
 - in LMICs, 129–30
 - treatment of, 129–30
 - acute myeloid leukemia, 197
 - acute promyelocytic leukemia (APL), 126*b*
 - incidence and death rates, 6*t*, 28*f*
 - childhood, 121–23, 122*f*
 - radiation therapy for, 240
- leukoplakia, 90
- Levin, Carol, 69, 249, 295
- Libya, cervical cancer in, 71
- lifestyle
- breast cancer and, 45, 47
 - cancer and, 23–24, 29, 32, 38
 - colorectal cancer and, 105, 114, 217
- Lipscomb, Joseph, 45
- liver cancer, 147–64
- aflatoxins and, 11, 150, 151, 153, 156–57, 159
 - alcohol consumption and, 153–54, 157
 - cost-effectiveness of interventions, 13, 13*f*, 158–60, 268, 273–74*t*
 - costs of treating, 159–60
 - global burden of, 147–50
 - HCC (hepatocellular carcinoma) as most common type, 147
 - incidence and death rates, 6*t*, 8*f*, 27–29, 28*f*, 147–49, 148*m*
 - age-specific incidence, 149
 - by gender, 148*m*, 149, 215
 - by income groups, 149–50, 150*f*
 - trends, 150
 - liver fluke infection, 11–12, 149, 154, 157–58, 277
 - obesity and, 147, 154
 - prognosis and DALYs, 150, 158
 - research support for, 259–60
 - risk factors, 150–54, 160*t*. *See also* hepatitis B and C viruses
 - treatment of, 9*t*, 158, 160, 160*t*. *See also* hepatitis B vaccination
 - vaccination programs for, 32, 154–56. *See also* hepatitis B vaccination
- London, W. Thomas, 147
- low- and middle-income countries (LMICs)
- air pollution in, 38
 - alcohol consumption in, 157. *See also* alcohol consumption
 - breast cancer in, 45, 215–16. *See also* breast cancer compared to HICs, 216
 - cost-effective interventions, 59–61
 - early-stage treatment, 12*b*
 - incidence and death rates, 27, 59
 - Burkitt lymphoma in, 134. *See also* Burkitt lymphoma
 - cancer incidence and death rates in, 2–3*m*, 4*b*,

- 6t, 8f, 17, 27, 165, 166. *See also specific types of cancer*
 - cancer screening priorities in, 218. *See also cancer screening*
 - cancer statistics, need to compile and monitor in, 24, 26, 39
 - cancer survival rates in, 1
 - cancer transition in, 29–32
 - cervical cancer in, 69, 70f. *See also cervical cancer regional burden, 71, 71m screening programs, 75, 216–17 treatment, 78*
 - childhood cancer in, 123. *See also childhood cancer*
 - colorectal cancer in, 108. *See also colorectal cancer international partnership arrangements to support treatment, 111 screening programs, 217*
 - comprehensive cancer centers in, 196. *See also comprehensive cancer centers*
 - cost-effectiveness of interventions in, 13, 13f, 267–69, 270, 275, 276–77t, 277. *See also cost-effectiveness*
 - costs of cancer control in, 4b, 14t. *See also costs delayed presentation for cancer as norm in, 213–14, 234, 282, 290*
 - economic overview, 263–64. *See also cost-effectiveness*
 - financing cancer care in, 15, 281
 - HPV vaccination programs in, 10, 77. *See also HPV vaccination*
 - inadequate resources in, 264
 - intervention packages in, 9–10
 - laboratories in, 265
 - liver cancer in, 150. *See also liver cancer*
 - lung cancer in, 177. *See also lung cancer noncommunicable diseases, death rates in, 24, 24f oral cancer in, 85, 89. See also oral cancer cost-effectiveness assessments of preventing and screening, 94–96 future research needs, 96 pain control in, 166–71. See also pain relief radiation therapy in, 239, 265. See also radiation therapy*
 - retinoblastoma in, 137
 - surgery in, 223, 229–30t, 233–34b, 264–65. *See also surgery*
 - tobacco use in, 23, 35–36. *See also tobacco use affordability and, 182 smoking cessation patterns, 180 Westernized lifestyle adopted in, 24, 29, 217*
 - low-income countries (LICs). *See low- and middle-income countries (LMICs)*
 - lung cancer
 - air pollution and, 38
 - asbestos exposure and, 38
 - burden of, 29–30
 - gender differences, 29, 177–78, 215
 - by geographical region, 29, 177
 - incidence and death rates, 8f, 27–29, 28f, 215
 - by income group, 29
 - radiation therapy for, 240
 - Luo, X. Q., 131
 - Luxembourg, cervical cancer screening in, 74
 - lymphoma. *See also Burkitt lymphoma; Hodgkin lymphoma*
 - incidence and death rates, 28f
 - radiation therapy for, 240
- M**
- MacLennan, Mary, 175
 - Madagascar
 - cervical cancer screening in, 75
 - HPV vaccination in, 78
 - Malawi
 - Burkitt lymphoma in, 137
 - cervical cancer in, 71, 75
 - childhood cancer in, 139
 - HPV vaccination in, 78
 - nonphysicians performing surgery in, 232
 - Malaysia
 - cervical cancer prevention approaches in, 80
 - liver fluke infection in, 154
 - referral hospital in, 61
 - mammograms, 10–11, 29, 45, 49–51, 51t, 57–58, 63, 212, 214, 215–16, 277, 290
 - mastectomy, 54, 55t
 - mate drinking, as risk factor for oral cancer, 90
 - maternal health policy as umbrella for breast and cervical cancer, 219
 - Mauritius, inverse relationship of consumption and price of smoking in, 183
 - McGlynn, Katherine A., 147
 - MD Anderson Cancer Center at the University of Texas, 111
 - medical records, 250
 - medications. *See drug therapy*
 - men, cancer incidence and mortality of. *See gender differences*
 - Merck, 78, 299
 - methodology, 7b
 - Metzger, Monika L., 121
 - Mexico
 - breast cancer, national health insurance coverage of, 1, 291
 - cancer services guidelines in, 198
 - catastrophic health expenditures in, 290

cervical cancer in, 80, 266
 childhood cancer in, 1, 125, 204
 liver cancer in, 149
 Oportunidades program in, 284
 percent of total health spending to cancer control in, 15
 Seguro Popular (national public insurance program), 1, 125, 204, 266, 283, 284, 287*t*, 291
 smoking in
 cigarette taxes in, 10
 inverse relationship of consumption and price, 183
 knowledge of health information, 184
 survival rates due to improved coverage in, 291
 universal health care in, 284
 m-Health models, 218
 Middle East and North Africa. *See also specific countries*
 bladder cancer in, 12
 cervical cancer in, 71
 colorectal cancer in, 111
 HPV vaccination in, 79
 types of cancer in, 29
 middle-income countries (MICs). *See low- and middle-income countries (LMICs)*
 Million Death Study (India), 39
 ministries' research role, 249–50, 251*b*
 mobile phones, use of, 218
 Moldova, pain medications in, 167
 Mongolia
 HBV vaccination program in, 149
 HCV infection in, 151, 155
 liver cancer in, 29, 149
 opioid accessibility in, 169
 morphine, 166, 168, 170, 265*t*
 mortality rates. *See cancer death rates*
 Muñoz, N., 257
 Murillo, Raul H., 45
 Muslim countries
 alcohol consumption levels in, 37
 breast cancer screening in, 58
 Myanmar, cervical cancer screening in, 74

N
 NAFD (non-alcoholic fatty liver disease), 147, 154
 Namibia, childhood cancer in, 121
 National Cancer Institute (U.S.), 215, 255
 Surveillance, Epidemiology, and End Results (SEER) Program (U.S.), 251–52
 National Comprehensive Cancer Network, 111, 198
 National Institute for Health and Care Excellence (UK), 267
 National Institute of Alcohol Abuse and Alcoholism (NIAAA), 153–54
 national strategies
 cancer research, commitments to, 249–62. *See also* research support
 cancer services, universal health coverage of, 4*b*, 234
 collaboration, 256
 effectiveness of, 267
 intervention packages, 9*t*
 MIC national programs, 234
 Native Americans, retinoblastoma among, 137
 NCDs. *See noncommunicable diseases*
 neck cancer. *See head and neck cancers*
 needle biopsies, 54, 63
 Nepal
 B. P. Koirala Memorial Cancer Hospital, 206*b*
 cervical cancer in, 71
 HPV vaccination in, 78
 opioid accessibility in, 169, 170
 pain medications in, 167
 Netherlands, smoking restrictions in public places in, 185
 Network of National Cancer Institutions of Latin America (RINC) initiative, 245
 newborns, HPB vaccination for. *See hepatitis B vaccination*
 New Zealand. *See Australia/New Zealand*
 NGOs. *See nongovernmental organizations*
 NIAAA (National Institute of Alcohol Abuse and Alcoholism), 153–54
 Nicaragua, cervical cancer in, 71
 Niger
 domestic funding in, 282
 HPV vaccination in, 78
 Nigeria
 acute lymphoblastic leukemia (ALL) in, 128
 aflatoxins in, 159
 breast cancer in, 226
 cervical cancer screening in, 75
 costs of intervention packages in, 13
 non-alcoholic fatty liver disease (NAFD), 147, 154
 noncommunicable diseases (NCDs)
 allocation of development assistance for, 16
 cancer in comparison to other causes of death, 24, 24*f*
 surveillance systems for, 250–51, 252*t*
 tobacco as major contributor to, 187
 nongovernmental organizations (NGOs)
 cancer prevention activities and funding of, 139, 290
 research role of, 250, 256
 surgical capacity support from, 234*b*
 Nordhagen, S., 74
 Nordic countries. *See also specific countries*
 cervical cancer screening in, 73
 liver cancer in, 149, 150

- oral cancer in, 88
 - taxation to finance universal health coverage in, 284
 - Northern Africa. *See* Middle East and North Africa
 - Northern Ireland's greenways urbanization project, effect on chronic diseases, 38
 - North-South collaborations, 16, 257
 - Norway
 - advertising of cigarettes, ban on, 185
 - Ghana-Norway partnership as part of Breast Health Global Initiative, 199
 - opioid accessibility in, 170
 - Nurses' Health Study, 254, 254*b*
 - nut chewing, as oral cancer risk, 85, 87, 88–89
 - nutrition as risk factor for oral cancer, 89
- O**
- Obermeyer, Z., 74
 - obesity. *See also* lifestyle
 - relationship to cancer, 37–38
 - liver cancer, 147, 154
 - occult blood test. *See* colorectal cancer (CRC)
 - occupational risk factors, 38
 - Olson, Zachary, 295
 - Omar, Sherif, 195
 - opioid accessibility in, 168
 - opioid medications, 11, 165–69, 167*f*. *See also* pain relief
 - Opioid Price Watch (IAHPC), 167, 170
 - Opisthorchis viverrini*, 36
 - Oportunidades program (Mexico), 284
 - oral cancer, 85–99
 - alcohol consumption associated with, 37, 89
 - chemotherapy, 94, 275
 - chronic trauma as risk factor, 90
 - cost-effectiveness assessments of interventions, 94–96
 - cost-effectiveness of interventions, 94–96, 95*t*, 268, 274–75*t*
 - defined, 85
 - early diagnosis and staging of, 92, 93*t*
 - future research needs, 96
 - genetic factors, 89–90
 - high-risk screening, 212
 - HPV infection and, 87, 88, 90, 218
 - incidence and death rates, 6*t*, 28*f*, 85–88
 - by gender, 86*t*, 87–88*m*, 215
 - by income group, 87*f*, 224*f*
 - intervention packages, 9*t*
 - management of, 92
 - natural history of, 90
 - nutrition as risk factor, 89
 - oral potentially malignant disorders (OPMDs), screening for, 91
 - overview, 85
 - posttreatment follow-up, 94
 - prognosis, 94
 - radiation therapy for, 92–94, 240
 - research support for, 260
 - risk factors, 85–90, 218
 - screening for, 11, 90, 91–92, 218
 - health care personnel performing visual screening, 91
 - high-risk screening, 212
 - self-examination, 91–92
 - visual screening, 90–91, 277
 - surgery, 92–94, 228, 229–30*t*
 - complications of, 94
 - survival rates, 88
 - treatment of, 92–94
 - viruses as risk factor, 90
 - oral submucous fibrosis (OSMF), 89, 90
 - Organisation for Economic Co-operation and Development's Global Science Forum, 257
 - ovarian cancer
 - death rates from, 6*t*
 - high-risk screening, 58, 212
 - overdiagnosis concerns, 213, 215
 - oxycodone, 168, 170
- P**
- PAF (population attributable fraction), 26–27
 - pain relief, 165–73
 - availability of broadly defined palliative care services, 167
 - barriers in LMICs to, 167–69
 - cancer patients' need for, 166
 - comprehensive cancer center services, 200
 - cost-effectiveness of, 9, 169
 - costs of, 14*t*, 169–70
 - Global Opioid Policy Initiative (GOPI), 168, 170–71
 - as human right, 165
 - International Narcotics Control Board (INCB), 168
 - in LMICs, 166–67
 - opioid medications, availability of, 11, 166–67, 167*f*
 - Opioid Price Watch (IAHPC), 167, 170
 - overzealous regulation restricting access to, 168
 - patient perspective, 170
 - Pakistan
 - acute lymphoblastic leukemia (ALL) in, 128
 - HCV infection in, 151
 - incidence of HBV vs. HCV in, 151, 152*f*
 - oral cancer in, 87, 88, 94
 - Palestinian Authority, breast cancer screening in, 58
 - Palipudi, Krishna, 175
 - palliative care. *See also* pain relief

- radiation therapy and, 165, 240, 241
- surgery with palliative intent, 230
- pancreas cancer, 28*f*
- Pap smears, 69, 73, 74, 216
- Papua New Guinea, oral cancer in, 85
- Partners in Health, 199
- pathology
 - comprehensive cancer center services, 199
 - research role of, 252
 - surgery's reliance on, 226
 - telepathology, 218
- PBCRs (population-based cancer registries), 25, 39, 251
- pediatric cancer. *See* childhood cancer
- Pediatric Oncology in Developing Countries (PODC)
 - committee of International Society of Pediatric Oncology (SIOP), 125
- Peru
 - cervical cancer prevention approaches in, 80
 - universal health care in, 284, 287*t*, 289, 290
- Peto, Richard, 179
- pharmacotherapy. *See* chemotherapy
- pharmacy services. *See also* drug therapy
 - comprehensive cancer centers, 201
- pharynx. *See* oral cancer
- Philip Morris, 189
- Philippines
 - colorectal cancer incidence rates in, 103
 - opioid accessibility in, 170
 - smoking in
 - implementation of excise tax increases, 184
 - implications of tobacco taxation, 10, 188
 - inverse relationship of consumption and price, 183
- physical inactivity. *See* lifestyle
- “Pink Ribbon Red Ribbon” program, 219
- Poland
 - opioid accessibility in, 170
 - radiation therapy in, 245
 - smoking in
 - cessation treatments, 186
 - implementation of excise tax increases, 184
 - inverse relationship of consumption and price, 183
- popularity paradox, 215
- population attributable fraction (PAF), 26–27
- population-based cancer registries (PBCRs), 25, 39, 251
- population-based randomized trial, 62
- Pramesh, C. S., 223
- prevention strategies, 1, 10. *See also specific types of cancer*
- primary health clinic or mobile outreach, 9*t*
- priorities for international support, 16–17

- cost reduction for essential intervention
 - packages, 16
- research support, 17
- technical assistance, 16–17
- progressive universalism, 283
- prostate cancer
 - early detection as factor, 29
 - by geographical region, 29
 - incidence and death rates, 6*t*, 27, 28*f*
 - by income group, 32*f*
 - transitions in low- and middle-income countries, 29
 - overdiagnosis concerns, 213
 - physical inactivity, relationship to, 38
 - radiation therapy for, 240
 - research support for, 260
 - screening for, 10
 - lead-time bias and, 212
- prostate-specific antigen (PSA) testing, 10–11
- psychosocial support, 200
- public awareness of cancer control interventions, 16, 255
- public places, restrictions on smoking in, 185, 188

Q

- Qiao, You-Lin, 249, 295
- quality-adjusted life years (QALYs), 7*b*

R

- Rabeneck, Linda, 101, 268
- Radiation Safety Institute of Canada, 199
- radiation therapy (RT), 239–47. *See also specific types of cancer*
 - access to, 243–45, 244*m*
 - as adjuvant treatment, 231, 240
 - adoption of expert systems and machine learning methods, 243
 - brachytherapy, 241
 - comprehensive cancer center services, 199–200, 243
 - concurrent chemotherapy and, 240
 - constraints on, 265
 - cost-effectiveness of, 239
 - critical normal structures, limited tolerance of, 240
 - delivery methods, 241–43
 - equipment specialized for, 239, 265
 - externally applied radiation beams, 241
 - facilities designed for, 241–42
 - infrastructure requirements, 244, 265
 - integration into cancer centers, 243
 - intensity modulated radiation therapy (IMRT), 240
 - in multidisciplinary approach to cancer management, 239
 - oral cancer, 94

- overview, 239–40
 - palliative treatment and, 165, 240, 241
 - personnel and radiation therapists, 242, 244
 - process, 242
 - radioisotope therapy, 241
 - safety and quality assurance, 242–43
 - scaling up, 15, 275
 - as sole therapy, 240
 - stereotactic RT, 240
 - uses of, 240–41
 - Rajaraman, Preetha, 249
 - Ramadas, Kunnambath, 85
 - Ramasundarahettige, Chintanie, 175
 - raw fish consumption, 157
 - Reach for Recovery, 58
 - Rebbeck, Timothy, 249
 - rectal cancer, 110. *See also* colorectal cancer
 - referrals, 214
 - surgery, 231–32
 - regional cancer centers, establishment of, 203, 203–4*b*
 - registries
 - childhood cancer incidence rates in, 121, 122*f*
 - death registration systems, linking to cancer registration systems, 253
 - global initiative for cancer registry through IARC, 40, 40*m*
 - importance of, 266
 - population-based cancer registries (PBCRs), 25, 39, 251
 - types of data in, 250–52
 - reproductive health policy as umbrella for breast and cervical cancer, 219
 - Republic of Korea. *See* Korea, Republic of
 - research support, 17, 249–62
 - “best buys,” 259–60
 - biobanking, 252–53
 - budget allocation recommended for, 249
 - Call to Action for Research on Health (2008 Bamako Forum), 249, 250*b*
 - cancer registries, data in, 250–52
 - case-control studies, 253
 - cervical cancer as integrated research exemplar, 257–59
 - cohort studies, 254, 254–55*b*
 - collaboration, 256
 - education to include, 256
 - epidemiologic studies, 253–57, 260
 - health care professionals’ role in, 250
 - health communications, 255
 - health surveillance and cancer surveillance, 250–51
 - hospitals’ role in, 250
 - implementation science, 255–56, 256*b*
 - as “best buy” for cancer research, 259
 - industry collaboration, 257
 - international collaboration, 257
 - laboratories and anatomic pathology, 252
 - linking death registration systems to cancer registration systems, 253
 - local level collaboration, 256
 - ministries’ role in, 249–50
 - national level collaboration, 256
 - overview, 249
 - priorities in cancer research, 250–57
 - research training, 256–57
 - stakeholders’ knowledge needs and, 249–50, 251*b*
 - transport of specimens among countries, 253, 256
 - resource limitations
 - availability across countries, 264–67
 - comprehensive cancer centers, 202–5
 - need for guidelines to address, 48–49
 - surgery, 226–27, 227*b*
 - retinoblastoma, 137–38
 - Rodriguez-Galindo, Carlos, 121
 - Romania, opioid accessibility in, 169, 170
 - Russia
 - alcohol consumption levels in, 37
 - breast cancer detection in, 52
 - colon cancer incidence and mortality in, 266
 - HCV treatment in, 156
 - health insurance coverage in, 266
 - liver cancer, cost of treatment in, 159
 - liver fluke infection in, 154
 - oral cancer in, 88
 - smoking in, 180
 - knowledge of health information, 184
 - price elasticity, 181
 - Rwanda
 - cervical screening and treatment services in, 228
 - HPV vaccination program in, 78
 - opioid accessibility in, 169
 - Rwandan Women’s Interassociation Study and Assessment, 73
- S**
- St. Jude Children’s Research Hospital (Memphis, Tennessee), 130, 136, 204, 205*b*
 - Sankaranarayanan, Rengaswamy, 1, 85, 114, 217, 258, 268
 - Sauvaget, C., 114, 217
 - Sayginsoy, O., 187
 - scaling up
 - cancer screening projects, 214
 - chemotherapy, 16, 275
 - childhood cancer, 277
 - hepatitis B vaccination, 15
 - HPV vaccination, 15
 - surgical systems, 234–35

Schistosoma haematobium, 36
 schistosomiasis, 12
 screening. *See* cancer screening; *specific types of cancer*
 secondhand smoke, 175
 SEER (Surveillance, Epidemiology, and End Results) Program, 102
 Seguro Popular (Mexico), 1, 125, 204, 266, 283, 284, 287*t*, 291
 self-examination
 breast self-examination, 52, 216
 oral cancer screening, 91–92
 Sharma, Monisha, 295
 Shi, Ju-Fang, 295
 Shulman, L., 214
 Sierra Leone, HPV vaccination in, 78
 simeprevir, 155–56, 159
 Singapore
 colorectal cancer in, 108, 111
 head and neck cancers, imaging techniques for, 198
 health insurance coverage in, 289
 liver fluke infection in, 154
 oral cancer in, 88
 Single Convention on Narcotic Drugs of 1961, 168
 SIOP (International Society of Pediatric Oncology), 125
 skilled medical personnel, 266
 skin cancer, 38, 240, 260
 Slovak Republic, oral cancer in, 87, 88
 smoking. *See* tobacco use
 smuggling and black market sales of cigarettes, 186–87
 sociocultural beliefs. *See* cultural practices
 Soerjomataram, Isabelle, 23
 sofosbuvir, 155–56, 159
 South Africa
 breast cancer and access to treatment in, 225
 cervical cancer prevention approaches in, 80, 217
 national health insurance package in, 15
 smoking in
 cigarette taxes, 10, 184
 inverse relationship of consumption and price, 183, 183*f*
 reporting on death certificates, 185
 smuggling and black market sales of cigarettes, 187
 South Asia
 catastrophic health expenditures in, 282
 colorectal cancer in, 38, 102
 HBV infection in, 151
 HCV infection in, 155
 head and neck cancers in, 198
 high-risk screening for oral cancer in, 212
 imaging techniques guidelines for head and neck cancers, 198
 liver cancer in, 147
 oral cancer in, 85, 87, 89, 212, 218
 tobacco use in, 175
 Southeast Asia
 aflatoxins in, 153
 alcohol consumption in, 157
 breast cancer in, 60
 colorectal cancer in, 38, 114
 oral cancer screening in, 87, 218
 high-risk screening, 212
 South-South collaborations, 16, 257
 Spain
 liver cancer in, 149
 opioid accessibility in, 170
 smuggling and black market sales of cigarettes in, 187
 specialized cancer centers/units. *See also* comprehensive cancer centers
 childhood cancer dedicated centers, 123–24, 124*t*, 128
 intervention packages, 9*t*
 scaling up, 16
 Standards of Oncology Pharmacy Practice, 201
 Stevens, Lisa, 249
 stomach cancer
 diet and consumption associated with, 37
 incidence and death rates, 6*t*, 8*f*, 27, 28*f*, 215, 218
 decline in, 29
 by income group, 35*f*
 research support for, 260
 schistosomiasis and, 12
 screening for, 218
 stroke, smoking's relationship to, 178, 184
 Subramanian, Sujha, 85
 Sub-Saharan Africa
 alcohol consumption in, 157
 antiretroviral therapy in, 73
 Burkitt lymphoma in, 123, 134
 cancer incidence and death rates in, 166
 cancer trends in, 29
 cervical cancer in, 23, 71, 71*m*
 childhood cancer in, 121
 costs of intervention packages in, 13–14
 HBV infection in, 151
 HCV infection in, 155
 HPV vaccination in, 10, 79
 liver cancer in, 147, 149, 151
 national health insurance coverage in, 290
 radiation therapy in, 244, 265, 266
 resource constraints in, 264
 retinoblastoma in, 137
 surgical infrastructure needed in, 223
 Substance Abuse and Mental Health Services Administration, 255–56

- Sudan
 - cervical cancer in, 71
 - opioid accessibility in, 170
 - oral cancer, smokeless tobacco products as factor in, 89
 - pain medications in, 167
 - Sullivan, Richard, 211, 223
 - Sullivan, Terrence, 211
 - surgery, 223–38
 - access to, 225, 225*t*
 - adjuvant treatment considerations, 230–31, 240
 - anesthesia, safe provision of, 226
 - biopsy procedures, 227–28
 - breast cancer, 12*b*, 54, 55–56*t*, 223
 - burden of surgically treatable cancers in LMICs, 224, 224*f*, 236
 - capacity building, 232–35
 - centralized vs. decentralized delivery models, 231, 231*t*
 - cervical cancer, 78
 - colon cancer, 110, 223
 - comprehensive cancer center services, 199
 - costs and cost-effectiveness of, 235–36, 267
 - diagnostic role of, 227
 - distribution of services, 225
 - guidelines for surgical platforms, 227–31
 - imaging in conjunction with, 226
 - infrastructure and training, 225–26, 232–33, 264–65
 - need for further study to assess effectiveness of, 235, 236, 267
 - nonphysician providers, task shifting to, 232
 - oral cancer, 92–94
 - complications of, 94
 - overview, 223
 - pain relief and, 165
 - pathology in conjunction with, 226
 - platforms for delivery, 227–31, 228–30*t*
 - private vs. public sector provision of services, 234
 - procurement processes, 233
 - quality and safety, 225–26, 233, 233–34*b*
 - rectal cancer, 110
 - referral networks, service coordination, and partnerships, 231–32
 - resources
 - availability across countries, 264–65, 265*t*
 - stratified approaches by level of care, 226–27, 227*b*
 - scaling up, 15, 16, 234–35
 - shortage of surgeons in LMICs, 232–33
 - standardization of guidelines, 225
 - status in LMICs, 224–25
 - surgical missions, 232
 - treatment with curative intent, 228–30
 - treatment with palliative intent, 230
 - utilization of services, 225
 - workforce development for, 232–33
 - Surveillance, Epidemiology, and End Results (SEER) Program, 102
 - surveillance systems, 250–51, 252*t*
 - as “best buy” for cancer research, 259
 - need for, 24, 26, 39–40
 - survivorship programs, 200
 - Sweden
 - alcohol consumption levels in, 37
 - cervical cancer treatment in, 16
 - Switzerland, smoking in
 - knowledge of health risks associated with, 185
 - possible tax increase on cigarettes, 184
 - treaty with Uruguay as basis for lawsuit, 189
- T**
- Taiwan
 - colorectal cancer in, 108, 111
 - HCV infection in, 151
 - hepatitis B vaccination in, 36
 - incidence of HBV vs. HCV in, 151, 152*f*
 - liver cancer in, 149, 159
 - oral cancer in, 85, 87, 92
 - tamoxifen, 12*b*, 54, 60, 231, 265*t*
 - Tanzania
 - cervical cancer screening in, 75
 - HPV vaccination in, 78
 - technical assistance, need to prioritize, 16–17
 - telemedicine, 218
 - telepathology, 218
 - Thailand
 - care availability, outcomes of increasing, 291
 - cervical cancer prevention approaches in, 80–81, 292
 - colorectal cancer in, 103, 108, 217
 - financing of cancer interventions from taxes in, 290
 - liver cancer in, 149
 - liver fluke infection in, 149, 154, 158
 - oral cancer in, 88, 94
 - smoking in
 - implications of tobacco taxation, 188
 - inverse relationship of consumption and price, 183
 - knowledge of health information, 185
 - universal health care in, 284, 288*t*, 289, 290
 - co-payments, 291
 - Thomas, David B., 45
 - Three-Step Analgesic Ladder (WHO), 166
 - Thun, M. J., 254
 - thyroid cancer
 - by geographical region, 29
 - incidence and death rates, 28*f*

- tissue sampling, 54, 63, 227–28
- tobacco taxes, 180–84
 - ad valorem taxes, 182
 - affordability and, 182
 - cost-effectiveness of, 13, 13*f*, 187
 - discouraging youth smoking, 10, 182
 - financing of cancer interventions from, 15, 290
 - implementation of large tax increases, 183–84, 183*f*
 - poverty considerations, 188
 - price elasticity of demand for tobacco, 181–82
 - signaling effects of price increases, 184
 - smart excise tax structure, 182–83, 184*f*
- tobacco use, 175–93. *See also* oral cancer; tobacco taxes
 - advertising of cigarettes, 185, 189
 - cancer and other diseases resulting from, 176–78
 - chronic lung disease and, 178
 - colorectal cancer and, 32
 - cost-effectiveness of tobacco control, 187–88, 187–88*t*
 - current global volume of, 180
 - e-cigarettes, 186
 - epidemiology of smoking-attributable diseases, 175–79
 - Framework Convention on Tobacco Control (FCTC), 10, 89, 188, 189
 - future burden of cancer and, 32, 34–36, 179
 - gender differences in, 29–30, 176, 177*f*, 180
 - Global Adult Tobacco Survey, 182, 184
 - globalization and, 189
 - Global Youth Tobacco Survey, 182
 - individuals who start smoking in adolescence or early adult life, 176, 176*t*, 177*f*, 181*t*
 - international initiatives, 189
 - intervention packages, 9*t*
 - cost-effectiveness of, 8
 - costs of, 14*t*
 - effectiveness of, 10, 182*t*
 - mortality rates, 35, 175, 179
 - avoidable deaths before 2050, 189
 - cessation of use, effect on, 178
 - in LMICs, 178–79
 - smoking's delayed effect on, 175–76
 - plain packaging mandate, 185, 189
 - population attributable fraction (PAF) and, 26
 - poverty considerations for, 188
 - public places, restrictions on smoking in, 185, 188
 - as risk factor, 23, 85, 87, 88–89
 - smokeless tobacco use, 88–89
 - smoking cessation
 - counseling and cessation support programs, 186
 - health information and counter-advertising, 184–85
 - interventions to increase, 180–87. *See also* tobacco taxes
 - patterns, 180
 - smuggling and black market sales of cigarettes, 186–87
 - supply-side interventions, 186–87
 - tuberculosis and, 178
 - Uruguay case study of tobacco control, 188–89
 - U.S. ban of clove-flavored cigarettes, WTO suit over, 189
 - WTO suits involving cigarettes, 189
 - traditional medicine, 155
 - training of health care professionals, 203–4
 - in radiation therapy, 244
 - surgeons and surgical staff, 225–26, 232–33
 - transport of specimens among countries, 253, 256
 - trastuzumab, 12*b*, 290
 - Trimble, Edward L., 249
 - Trypuc, Joann, 195
 - tuberculosis, 176, 178
 - Tufts Medical Center Cost-Effectiveness Analysis Registry of cancer-related studies, 235
 - tumor lysis syndrome (TLS), 135
 - Tunisia, cervical cancer in, 71
 - Turkey
 - financing approach in, 283
 - radiation therapy in, 245
 - smoking, inverse relationship of consumption and price in, 183
 - twinning programs
 - childhood cancer treatment, 124–25, 130, 140
 - development of cancer centers and, 205
 - examples of, 205–6*b*, 267
 - innovative approaches and, 218
 - pathology and laboratory medicine, 199
 - survival rates improved by, 205
- U**
- Uganda
 - alcohol consumption levels in, 37
 - cancer trends in, 29
 - cervical cancer in, 23, 75
 - opioid accessibility in, 169
- Uganda Cancer Institute, 205*b*
- ultrasound in breast cancer diagnosis, 54, 216
- Unidad Nacional de Oncología Pediátrica (UNOP, Guatemala), 140
- Union for International Cancer Control (UICC), 197*b*
 - Global Task Force on Radiotherapy for Cancer Control, 245
 - Tumor, Nodes, Metastasis (TNM) staging system, 92
- United Kingdom
 - asbestos exposure and lung cancer in, 38

- breast cancer, new drug treatments for, 13
 - British doctors, cohort study of, 254
 - British Royal College of Physicians, 185
 - HCV treatment in, 156
 - National Institute for Health and Care Excellence, 267
 - opioid accessibility in, 170
 - oral cancer in, 88
 - quitting smoking's effect on mortality in, 178
 - salt intake, related to cancer rate in, 37
 - smoking in
 - effect on mortality in, 175–76, 177*f*
 - inverse relationship of consumption and price, 183, 183*f*
 - quitting, effect on cancer, 178, 180
 - taxation to finance universal health coverage in, 284
 - United Kingdom Million Women Study, 254
 - United Nations (UN)
 - demographic estimates of cancer mortality, 7*b*
 - Sustainable Development Goals for 2030, 1
 - United Nations Population Fund, 219
 - United Nations World Population Prospects, 26
 - United States
 - acute lymphoblastic leukemia (ALL) in, 128
 - alcohol consumption in, 157
 - cancer registries in, 266
 - colorectal cancer incidence rates in, 102
 - cost-effectiveness in, 267
 - incidence of HBV vs. HCV in, 151, 152*f*
 - liver cancer in, 149, 150
 - liver cirrhosis in, 154
 - lung cancer in, 177
 - asbestos exposure and, 38
 - opioids for pain relief in, 169
 - oral cancer, smokeless tobacco products as factor for, 89
 - smoking in, 180
 - advertising of cigarettes, 185
 - ban of clove-flavored cigarettes, WTO suit over, 181–82
 - e-cigarettes, 186
 - effect on mortality in, 176, 177*f*
 - implementation of excise tax increases, 184, 187
 - inverse relationship of consumption and price, 183, 183*f*
 - price elasticity, 181–82
 - quitting, effect on mortality, 178, 179*f*
 - U.S. Surgeon General's Report, 185
 - youth quitting, 184
 - surgery in, 236
 - universal health coverage. *See* health insurance
 - urbanization, 263, 277
 - Uruguay
 - colorectal cancer in, 11
 - oral cancer in, 85
 - tobacco control in, 188–89
 - U.S. Community Preventive Services Task Force, 157
 - U.S. Multi-Society Task Force on CRC/American Cancer Society (USMSTF), 107, 108
 - U.S. Preventive Services Task Force (USPSTF), 10–11
 - on breast self-examination, 52
 - on clinical breast examination, 51
 - on colorectal screenings, 107–8
 - on mammogram screenings, 50, 51*t*
 - on oral cancer, 91, 218
 - on screening guidelines, 198
 - U.S. Surgeon General's Report, 185
- V**
- vaccines. *See* hepatitis B (HBV) vaccination; HPV (human papillomavirus) vaccination
 - Verguet, Stéphane, 295
 - Victoria Hospice (Victoria, British Columbia), 206*b*
 - Vietnam
 - breast cancer in
 - clinical breast examinations, 60
 - surgical treatment costs, 235
 - liver cancer in, 149
 - liver fluke infection in, 154
 - opioid accessibility in, 168–69
 - smoking in
 - affordability, 182
 - implications of tobacco taxation, 188
 - knowledge of health information, 184
 - Vos, T., 267
- W**
- Wagner, Judith, 165
 - Wang, Shao-Ming, 295
 - Wee, J. T., 198
 - Welch, Gilbert, 215
 - West Africa, aflatoxins in, 157
 - WHO. *See* World Health Organization
 - Wild, Christopher P., 147
 - Wilms tumor, 11, 126, 133–34, 133*t*, 135*t*
 - Wilson-Junger screening criteria, 213, 213*b*
 - women. *See also* gender differences
 - breast cancer. *See* breast cancer
 - cervical cancer. *See* cervical cancer
 - ovarian cancer. *See* ovarian cancer
 - World Development Report* (1993), 5*b*
 - World Economic Forum/Harvard School of Public Health, 218
 - World Endoscopy Organization, 109
 - World Endoscopy Society, 267
 - World Health Assembly

- premature death, goal to reduce, 1
 - smoking, goal to reduce, 189
 - World Health Organization (WHO). *See also*
 - International Agency for Research on Cancer (IARC)
 - on breast cancer guidelines, 48
 - cervical cancer screening, VIA demonstration project, 75
 - Choosing Interventions That Are Cost-Effective (WHO-CHOICE) framework, 59, 60, 277
 - on cigarette excise taxes, 183–84
 - collection of cancer incidence, 39
 - on cost-effective intervention strategies for NCDs in LMICs, 218
 - cost effectiveness recommendations, 60, 138, 235
 - on effectiveness of tobacco control, HPV and HBV vaccination, and opportunistic cervical cancer screening, 17
 - EPIC model to simulate the macroeconomic effects of noncommunicable diseases, 187, 187*t*
 - Essential Medicines List, 156, 166, 170
 - Framework Convention on Tobacco Control (FCTC), 10, 89, 188, 189
 - Global Health Estimates, 7*b*
 - Global Health Observatory, 250
 - Global Monitoring Framework for Noncommunicable Diseases, 166
 - on HBV vaccine, 155
 - on HCV infection, 151
 - on health expenditures covered by external sources, 282, 283
 - on imaging guidelines, 199
 - on life table estimates for China, 297
 - mortality databank, 26
 - MPOWER report on global tobacco epidemic, 36
 - on national cancer control planning, 195, 243, 267
 - on noncommunicable disease best buys for LMICs, 8
 - on palliative care, 165, 168
 - Study of Global AGEing and Adult Health, 298
 - Surgical Safety Checklist, 199
 - Three-Step Analgesic Ladder, 166
 - WHO Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases*, 39
 - World Trade Organization (WTO), 189
- Y**
- Yerramilli, Pooja, 281
 - Yip, Cheng-Har, 223
 - youth smoking, 10, 182, 184, 186
 - Yurekli, Ayda, 175, 187
- Z**
- Zambia, cervical cancer in, 71, 75
 - Zatoński, Witold, 175
 - Zauber, Ann G., 101
 - Zelle, S. G., 59, 60, 216
 - Zhao, Fang-hui, 249
 - Zimbabwe
 - cancer trends in, 29
 - cervical cancer, increases in, 23
 - zur Hausen, H., 257

ECO-AUDIT

Environmental Benefits Statement

The World Bank Group is committed to reducing its environmental footprint. In support of this commitment, the Publishing and Knowledge Division leverages electronic publishing options and print-on-demand technology, which is located in regional hubs worldwide. Together, these initiatives enable print runs to be lowered and shipping distances decreased, resulting in reduced paper consumption, chemical use, greenhouse gas emissions, and waste.

The Publishing and Knowledge Division follows the recommended standards for paper use set by the Green Press Initiative. The majority of our books are printed on Forest Stewardship Council (FSC)–certified paper, with nearly all containing 50–100 percent recycled content. The recycled fiber in our book paper is either unbleached or bleached using totally chlorine free (TCF), processed chlorine free (PCF), or enhanced elemental chlorine free (EECF) processes.

More information about the Bank’s environmental philosophy can be found at <http://crinfo.worldbank.org/wbcrinfo/node/4>.



The DCP02 series is a family of 2W, isolated, unregulated DC/DC converters. Requiring a minimum of external components and including on-chip device protection, the DCP02 series provides extra features such as output disable and synchronization of switching frequencies. The use of a highly integrated package design results in highly reliable products with power densities of 79W/in³ (4.8W/cm³) for DIP-14, and 106W/in³ (6.5W/cm³) for SO-28. This combination of features and small size makes the DCP02 suitable for a wide range of applications. Sync/disable vs. Turn the DCP on, launch DCP Manager and follow the prompts on screen. Refer to the Help Files for instructions on how to configure the basic operating parameters of the DCP (source inputs, format, presets, etc).

4. Attach Amplifiers. Connect DataPort outputs on the DCP rear panel to DataPort inputs on QSC's DCA or PL3 Series amplifiers using QSC approved DataPort cables.

11. Setup Overview. DCP work included an expansive portfolio advancing methodological approaches to economic evaluation, engaging with users and decision-makers in low- and middle-income countries, and contributing to the global knowledge base through journal publications, working paper series, and the development of topic-specific derivative products. The DCP-Gender initiative examined the impact of DCP3 Essential Universal Health Care packages on women and girls in low- and middle-income countries. [Read More](#).

Previous. DCP-o-matic will encode your DCP. This may take some time (many hours in some cases). While the job is in progress, DCP-o-matic will update you on how it is getting on with the progress bar in the bottom of its window, as shown in Figure 3.6.

Figure 3.6: Making the DCP. When it has finished, the DCP will end up on your disk inside the Im's folder. You can then copy this to a projector via a USB stick, hard-drive or network connection.

Installed products: vxs series, XMV series, mrx series, EXi8, dcp series.

6. Yamaha Commercial Installation Solutions are designed to help you deliver ideal sound in commercial spaces. A speaker system combined with an appropriate simple or smart solution can provide the perfect balance of performance and functionality for your needs.

Speaker Systems. VXS, VXL and VXC series speakers have been optimized specifically for commercial sound applications, with accurate sound inspired by our long history of musical instrument production plus visual design that blends easily with any décor. Choose th